{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Michaelgibson.jpg|frameless|upright=0.3|center]]
|<big>[[User:Michaelgibson|Michael Gibson, MD, PhD]]<br>Vanderbilt University<br>Nashville, TN</big><br>Twitter: [https://twitter.com/mgibson21212 mgibson21212]<br>[https://www.linkedin.com/in/michael-gibson-65137032/ LinkedIn]
|-
|}
''Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the [[Head_and_neck_cancer_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
*'''Note: this page contains regimens which are not histology or biomarker-specific, although they may have been studied in patients selected by histology and/or biomarker. The following links will take you to specific subpages:''' 
*<big>Regimens for [[Oropharyngeal_cancer,_HPV-positive|'''HPV positive oropharyngeal cancer are here''']]</big>.
*<big>Regimens for [[Nasopharyngeal carcinoma|'''nasopharyngeal carcinoma are here''']]</big>.

{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[https://www.asco.org/ ASCO]==
*'''2017:''' Forastiere et al. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.7385 Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/29172863 PubMed]
*'''2017:''' Nekhlyudov et al. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.8478 Head and neck cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement of the American Cancer Society guideline] [https://www.ncbi.nlm.nih.gov/pubmed/28240970 PubMed]

==EHNS/ESMO/ESTRO==
*'''2010:''' Gr√©goire et al. [http://annonc.oxfordjournals.org/content/21/suppl_5/v184.full.pdf+html Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/20555077 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf NCCN Guidelines - Head and Neck Cancers]

=Locally advanced disease, induction=
''Note that these regimens are intended to be followed by definitive radiotherapy or chemoradiotherapy. In some circumstances, treatment may be followed by surgery; if this sequence was pre-planned it would be considered a neoadjuvant approach as opposed to an induction approach.''
==Cisplatin & Fluorouracil {{#subobject:b5390f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin & '''<u>F</u>'''luorouracil
<br>PF: '''<u>P</u>'''latinol (Cisplatin) & '''<u>F</u>'''luorouracil

===Variant #1, 100/4000 {{#subobject:37c90b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa070956 Posner et al. 2007 (TAX 324)]
|style="background-color:#1a9851"|Phase III (C)
|[[#DCF|TPF]], then [[#Carboplatin_.26_RT|Carboplatin & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS (*)
|-
|}
''Reported efficacy is based on the 2011 update.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 30 to 180 minutes once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Carboplatin_.26_RT|Definitive carboplatin & RT]], 3 to 8 weeks after the start of cycle 3

===Variant #2, 100/5000, 2 cycles with response adaptation {{#subobject:62ca18|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031317 Forastiere et al. 2003 (RTOG 91-11)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#RTOG_91-11|See link]]
|[[Complex_multipart_regimens#RTOG_91-11|See link]]
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)

'''21-day cycle for 2 cycles''' 
====Subsequent treatment====
*After cycle 2, patients are evaluated by indirect laryngoscopy and CT neck.
**Patients with PR/CR receive a third cycle, then [[#Radiation_therapy|definitive RT]]
**Patients with worse than a PR: [[Surgery#Laryngectomy|Laryngectomy]], then [[#Radiation_therapy_2|adjuvant RT]]

===Variant #3, 100/5000 x 3 {{#subobject:fdece8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 Wolf et al. 1991]
|style="background-color:#1a9851"|Phase III (E)
|[[#Surgery|Surgery]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/12/2/385.long Taylor et al. 1994]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#d73027"|Inferior ORR
|-
|[http://jco.ascopubs.org/content/23/34/8636.long Hitt et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|[[#PCF.2C_then_Cisplatin_.26_RT|PCF, then Cisplatin & RT]]
|style="background-color:#d73027"|Inferior CR rate
|-
|[http://jnci.oxfordjournals.org/content/101/7/498.long Pointreau et al. 2009 (GORTEC 2000-01)]
|style="background-color:#1a9851"|Phase III (C)
|[[#DCF|TPF]], then [[#Radiation_therapy|RT]]
|style="background-color:#d73027"|Inferior ORR
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 Hitt et al. 2013 (TTCC XRP6976F/2503)]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 15 minutes once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)

====Supportive medications====
*Per '''GORTEC:''' Normal saline (use of mannitol, KCl, and magnesium sulfate per institutional protocol) 1000 mL IV given twice, before and after [[Cisplatin (Platinol)]]

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Wolf et al. 1991 & Taylor et al. 1994: [[#Radiation_therapy|Definitive RT]]
*Hitt et al. 2005: Patients then undergo ENT evaluation and CT imaging of the primary tumor and neck
**Patients with CR or PR of greater than 80% in the primary tumor and no evidence of progression in neck lymph nodes: [[#Cisplatin_.26_RT|Definitive cisplatin & RT]]
**Patients with a PR of less than 80% or stable disease in the neck lymph nodes (especially if N2 or N3 disease) after induction: [[Neck dissection]], if the surgeons were in agreement, before the administration of adjuvant chemoradiotherapy
**Patients with no response or progression of disease were taken off study
*GORTEC 2000-01: re-evaluation is performed 
**Patients who responded to induction chemotherapy: [[#Radiation_therapy|Definitive RT]] within 3 to 7 weeks of finishing chemotherapy
**Patients who did not respond to induction chemotherapy: [[Surgery#Head_and_neck_cancer_surgery|Surgery]], then [[#Radiation_therapy_2|adjuvant RT]] (see Pointreau et al. 2009 for details)
*TTCC XRP6976F/2503: [[#Cisplatin_.26_RT|Definitive cisplatin & RT]]

===Variant #4, 100/5000 x 4 {{#subobject:23fcf5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa071028 Vermorken et al. 2007 (EORTC 24971/TAX 323)]
|style="background-color:#1a9851"|Phase III (C)
|[[#DCF|TPF]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724854/ Lefebvre et al. 2009 (EORTC 24954)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#EORTC_24954|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#EORTC_24954|See link]]
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 5000 mg/m<sup>2</sup>)

====Supportive medications====
*"Adequate [[:Category:Emesis prevention|antiemetic]] medications during chemotherapy"
*Prophylactic [[Filgrastim (Neupogen)|G-CSF]] only allowed for patients who had "febrile neutropenia or infection, a delay in recovery of the absolute neutrophil count at day 28, or grade 4 neutropenia persisting for 7 days or more."

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*EORTC 24971/TAX 323: Patients without progressive disease and who had recovery of marrow function, resolution of mucositis, and healed from any dental procedures started [[#Radiation_therapy|definitive RT]] within 4 to 7 weeks of finishing chemotherapy
*EORTC 24954: [[#Radiation_therapy|Definitive RT]]

===References===
# Taylor SG 4th, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, Shott S, Vokes E, Showel JL, Hutchinson JC, Witt TR, Griem KL, Hartsell WF, Kies MS, Mittal B, Rebischung JL, Coupez DJ, Desphieux JL, Bobin S, LePajolec C. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994 Feb;12(2):385-95. [http://jco.ascopubs.org/content/12/2/385.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8113846 PubMed]
# '''RTOG 91-11:''' Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa031317 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14645636 PubMed]
## '''Update:''' Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/7/845.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577950/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182993 PubMed]
# Hitt R, L√≥pez-Pousa A, Mart√≠nez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Mart√≠ JL, Lobo F, Pastor P, Valent√≠ V, Bel√≥n J, S√°nchez MA, Chaib C, Pallar√©s C, Ant√≥n A, Cervantes A, Paz-Ares L, Cort√©s-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. [http://jco.ascopubs.org/content/23/34/8636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16275937 PubMed]
# '''EORTC 24971/TAX 323:''' Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704. [https://www.nejm.org/doi/full/10.1056/NEJMoa071028 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17960012 PubMed]
## '''QoL Analysis:''' van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010 Oct 12;103(8):1173-81. Epub 2010 Sep 14. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20842129 PubMed]
# '''TAX 324:''' Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15. [https://www.nejm.org/doi/full/10.1056/NEJMoa070956 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17960013 PubMed]
## '''Update:''' Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb;12(2):153-9. Epub 2011 Jan 11. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356902/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21233014 PubMed]
# '''EORTC 24954:''' Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. Epub 2009 Jan 27. [https://academic.oup.com/jnci/article/101/3/142/947754 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724854/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19176454 PubMed]
## '''Update:''' Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Gr√©goire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups. Long-term update of the 24954 EORTC phase III trial on larynx preservation. Eur J Cancer. 2016 Sep;65:109-12. Epub 2016 Aug 2. [https://www.ncbi.nlm.nih.gov/pubmed/27494036 PubMed]
# '''GORTEC 2000-01:''' Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. Epub 2009 Mar 24. [http://jnci.oxfordjournals.org/content/101/7/498.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19318632 PubMed]
## '''Update:''' Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ¬± docetaxel for larynx preservation. J Natl Cancer Inst. 2015 Dec 16;108(4). [https://academic.oup.com/jnci/article/108/4/djv368/2412557 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26681800 PubMed]
# '''TTCC XRP6976F/2503:''' Hitt R, Grau JJ, L√≥pez-Pousa A, Berrocal A, Garc√≠a-Gir√≥n C, Irigoyen A, Sastre J, Mart√≠nez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hern√°ndez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25. Epub 2013 Nov 19. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24256848 PubMed]

==No induction==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-abstract/86/4/265/894237 Paccagnella et al. 1994]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Fluorouracil|PF]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.43.8820 Zhong et al. 2012]
|style="background-color:#1a9851"|Phase III (C)
|[[#DCF|TPF]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 Hitt et al. 2013 (TTCC XRP6976F/2503)]
|style="background-color:#1a9851"|Phase II/III (C)
|1. [[#Cisplatin_.26_Fluorouracil|PF]]<br> 2. [[#DCF|TPF]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article/28/9/2206/3920776 Ghi et al. 2017 (GSTTC H&N07)]
|style="background-color:#1a9851"|Phase II/III (C)
|[[#DCF|TPF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''No treatment given prior to definitive therapy.''
====Subsequent treatment====
*Zhong et al. 2012: [[Surgery#Head_and_neck_cancer_surgery|Surgery]], then adjuvant RT
*TTCC XRP6976F/2503: [[#Cisplatin_.26_RT|Definitive cisplatin & RT]]
*GSTTC H&N07: Definitive [[#Cetuximab_.26_RT|cetuximab & RT]] or [[#Cisplatin.2C_Fluorouracil.2C_RT|cisplatin, 5-FU, RT]]

===References===
# Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A, Endrizzi L, Bari M, Sampognaro E, Balli M, Gava A, Pappagallo GL, Fiorention MV. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994 Feb 16;86(4):265-72. [https://academic.oup.com/jnci/article-abstract/86/4/265/894237 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8158680 PubMed]
## '''Update:''' Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, Boldrin F, Marchiori C, Lunghi F, Fede A, Bordin A, Da Mosto MC, Sileni VC, Orlando A, Jirillo A, Tomio L, Pappagallo GL, Ghi MG. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004 Nov 17;96(22):1714-7. [https://academic.oup.com/jnci/article/96/22/1714/2521051 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15547184 PubMed]
# '''PARADIGM:''' Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar;14(3):257-64. Epub 2013 Feb 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70011-1/fulltext link to original article] '''does not contain protocol in abstract''' [https://www.ncbi.nlm.nih.gov/pubmed/23414589 PubMed]
# Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20;31(6):744-51. Epub 2012 Nov 5. [http://ascopubs.org/doi/full/10.1200/JCO.2012.43.8820 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569675/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23129742 PubMed]
# '''TTCC XRP6976F/2503:''' Hitt R, Grau JJ, L√≥pez-Pousa A, Berrocal A, Garc√≠a-Gir√≥n C, Irigoyen A, Sastre J, Mart√≠nez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hern√°ndez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25. Epub 2013 Nov 19. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24256848 PubMed]
# '''GSTTC H&N07:''' Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codec√† C, Nol√® F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer: a phase II-III trial. Ann Oncol. 2017 Sep 1;28(9):2206-2212. [https://academic.oup.com/annonc/article/28/9/2206/3920776 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911070 PubMed]

==PCF {{#subobject:747f5e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PCF: '''<u>P</u>'''aclitaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>PPF: '''<u>P</u>'''aclitaxel, '''<u>P</u>'''latinol (Cisplatin), '''<u>F</u>'''luorouracil
===Regimen {{#subobject:2d319e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/13/10/1665.long Hitt et al. 2002]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/23/34/8636.long Hitt et al. 2005]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil|CF]]
|style="background-color:#1a9850"|Superior CR rate
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 2
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 2 (total dose per cycle: 2500 mg/m<sup>2</sup>)

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day on days 2 & 3
*[[Ondansetron (Zofran)]] 8 mg IV or PO Q8H or every 12 hours on days 1 to 5
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]] 
*[[Cimetidine (Tagamet)]] 300 mg IV once 30 minutes prior to [[Paclitaxel (Taxol)]]
**Per Hitt et al. 2005, [[Ranitidine (Zantac)]] (dose not specified) could be used instead
*Mannitol and IV hydration with [[Cisplatin (Platinol)]]

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Hitt et al. 2002: Patients undergo ENT evaluation and CT imaging of the primary tumor and neck during week 3 or 4 of cycle 3.
**Patients who did not have at least a PR were recommended for [[Surgery#Head_and_neck_cancer_surgery|surgery]], performed 4 weeks after cycle 3 day 1.
**Patients with bulky nodal disease prior to therapy "and/or suboptimal response to induction chemotherapy" were recommended for [[Surgery#Head_and_neck_cancer_surgery|neck dissection]], performed 4 weeks after cycle 3 day 1, then [[#Radiation_therapy_2|adjuvant RT]]
**Patients with PR/CR: [[#Paclitaxel_.26_RT|Definitive paclitaxel & RT]]; [[#Radiation_therapy|definitive RT]] alone was used "if concomitant treatment was not feasible."
*Hitt et al. 2005: Patients then undergo ENT evaluation and CT imaging of the primary tumor and neck. 
**Patients with CR or PR of greater than 80% in the primary tumor and no evidence of progression in neck lymph nodes: [[#Cisplatin_.26_RT|Definitive cisplatin & RT]]
**Patients with a PR of less than 80% or SD in the neck lymph nodes (especially if N2 or N3 disease) after induction CT: [[Surgery#Head_and_neck_cancer_surgery|Neck dissection]], "if the surgeons were in agreement, before the administration of CRT." 
**Patients with no response or progression of disease were taken off study

===References===
# Hitt R, Paz-Ares L, Brand√°riz A, Castellano D, Pe√±a C, Mill√°n JM, Calvo F, Ortiz de Urbina D, L√≥pez E, Alvarez-Vicent JJ, Cort√©s-Funes H. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol. 2002 Oct;13(10):1665-73. [http://annonc.oxfordjournals.org/content/13/10/1665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377658 PubMed]
# Hitt R, L√≥pez-Pousa A, Mart√≠nez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Mart√≠ JL, Lobo F, Pastor P, Valent√≠ V, Bel√≥n J, S√°nchez MA, Chaib C, Pallar√©s C, Ant√≥n A, Cervantes A, Paz-Ares L, Cort√©s-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. [http://jco.ascopubs.org/content/23/34/8636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16275937 PubMed]

==DCF {{#subobject:b86d78|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DCF: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>TPF: '''<u>T</u>'''axotere (Docetaxel), '''<u>P</u>'''latinol (Cisplatin), '''<u>F</u>'''luorouracil 
===Variant #1, 75/75/3750 x 2 {{#subobject:abb01b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.43.8820 Zhong et al. 2012]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)

'''21-day cycle for 2 cycles''' 
====Subsequent treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]], then [[#Radiation_therapy_2|adjuvant RT]]

===Variant #2, 75/75/3750 x 3 {{#subobject:5a590d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/101/7/498.long Pointreau et al. 2009 (GORTEC 2000-01)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil|CF]]
|style="background-color:#1a9850"|Superior ORR
|-
|[http://jco.ascopubs.org/content/31/7/853.long Lefebvre et al. 2013 (TREMPLIN)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 Hitt et al. 2013 (TTCC XRP6976F/2503)]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3750 mg/m<sup>2</sup>)

====Supportive medications====
*"Hydration was delivered according to institutional protocols."
*[[Dexamethasone (Decadron)]] 8 mg PO twice per day the day before, the day of, and day after [[Docetaxel (Taxotere)]]
*[[Ciprofloxacin (Cipro)]] 500 mg PO twice per day on days 5 to 15
*Prophylactic granulocyte colony-stimulating factor was not used. 
**[[:Category:Granulocyte colony-stimulating factors|G-CSF]] 150 mcg/m<sup>2</sup> SC once per day was used if febrile neutropenia occurred.
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonists]] given twice, before and after [[Cisplatin (Platinol)]]

'''21-day cycle for 3 cycles''' 
====Subsequent treatment====
*GORTEC, as follows: 
**Patients who responded to induction chemotherapy: [[#Radiation_therapy|Definitive RT]] within 3 to 7 weeks of finishing chemotherapy
**Patients who did not respond to induction chemotherapy: [[Surgery#Head_and_neck_cancer_surgery|Surgery]], then [[#Radiation_therapy_2|adjuvant RT]] (see Pointreau et al. 2009 for details)
*TREMPLIN: Restaging of disease takes place 2 weeks after finishing cycle 3. 
**Patients who had "at least 50% regression of their primary tumor volume and who recovered larynx mobility": Definitive [[#Cetuximab_.26_RT|cetuximab & RT]] versus [[#Cisplatin_.26_RT|cisplatin & RT]]
**Patients who did not have at least 50% regression: Salvage [[Surgery#Laryngectomy|total laryngectomy]]
*TTCC XRP6976F/2503: [[#Cisplatin_.26_RT|Definitive cisplatin & RT]]

===Variant #3, 75/75/3750 x 4 {{#subobject:6c7d09|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa071028 Vermorken et al. 2007 (EORTC 24971/TAX 323)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil|CF]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given second'''
*[[Fluorouracil (5-FU)]] 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given third''' (total dose per cycle: 3750 mg/m<sup>2</sup>)

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO for 6 doses (exact schedule not specified) starting the night before [[Docetaxel (Taxotere)]] 
*[[Ciprofloxacin (Cipro)]] 500 mg PO twice per day "or an alternative agent" on days 5 to 15 as prophylaxis
*"Adequate [[:Category:Emesis prevention|antiemetic]] medications during chemotherapy"
*Prophylactic [[Filgrastim (Neupogen)|granulocyte colony-stimulating factor]] only allowed for patients who had "febrile neutropenia or infection, a delay in recovery of the absolute neutrophil count at day 28, or grade 4 neutropenia persisting for 7 days or more."

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Patients without progressive disease and who had recovery of marrow function, resolution of mucositis, and healed from any dental procedures started [[#Radiation_therapy|definitive RT]] within 4 to 7 weeks of finishing chemotherapy

===Variant #4, 75/80/3200 {{#subobject:0c1fd9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/28/9/2206/3920776 Ghi et al. 2017 (GSTTC H&N07)]
|style="background-color:#1a9851"|Phase III (E)
|[[#No_induction|No induction]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3200 mg/m<sup>2</sup>)

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*Definitive [[#Cetuximab_.26_RT|cetuximab & RT]] or [[#Cisplatin.2C_Fluorouracil.2C_RT|cisplatin, 5-FU, RT]]

===Variant #5, 75/100/4000 x 2 {{#subobject:425bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967367/ Adelstein et al. 2010 (SWOG S0216)]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*Ciprofloxacin (Cipro) prophylaxis for 10 days (dose/route/precise schedule not specified)
*"Standard anti-emetics, hydration and diuresis"

'''21-day cycle for 2 cycles''' 
====Subsequent treatment====
*Restaging of disease takes place 3 weeks after finishing cycle 2. 
**Patients with SD or tumors which responded to therapy: [[#Cisplatin_.26_RT|Definitive cisplatin & RT]]
**Patients with progressive disease are considered--if possible--for [[Surgery#Head_and_neck_cancer_surgery|surgery]], then [[#Radiation_therapy_2|adjuvant RT]]. Patients who could not undergo surgery also received [[#Cisplatin_.26_RT|cisplatin & RT]]

===Variant #6, 75/100/4000 x 3 {{#subobject:3c426b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa070956 Posner et al. 2007 (TAX 324)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil|CF]]
|style="background-color:#91cf60"|Seems to have superior OS (*)
|-
|}
''Reported efficacy is based on the 2011 update.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given first'''
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 30 to 180 minutes once on day 1, '''given second'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1, '''given third''' (total dose per cycle: 4000 mg/m<sup>2</sup>) 

====Supportive medications====
*[[Dexamethasone (Decadron)]] used (dose, route, schedule not specified) to prevent [[Docetaxel (Taxotere)]]-related side effects
*Prophylactic antibiotics (further details not given) on days 5 to 14
*Prophylactic granulocyte colony-stimulating factor not allowed

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Carboplatin_.26_RT|Definitive carboplatin & RT]], 3 to 8 weeks after the start of cycle 3

===References===
# '''EORTC 24971/TAX 323:''' Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704. [https://www.nejm.org/doi/full/10.1056/NEJMoa071028 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17960012 PubMed]
## '''QoL Analysis:''' van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010 Oct 12;103(8):1173-81. Epub 2010 Sep 14. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20842129 PubMed]
# '''TAX 324:''' Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15. [https://www.nejm.org/doi/full/10.1056/NEJMoa070956 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17960013 PubMed]
## '''Update:''' Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb;12(2):153-9. Epub 2011 Jan 11. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356902/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21233014 PubMed]
# '''GORTEC 2000-01:''' Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. Epub 2009 Mar 24. [http://jnci.oxfordjournals.org/content/101/7/498.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19318632 PubMed]
## '''Update:''' Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ¬± docetaxel for larynx preservation. J Natl Cancer Inst. 2015 Dec 16;108(4). [https://academic.oup.com/jnci/article/108/4/djv368/2412557 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26681800 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''SWOG S0216:''' Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck. 2010 Feb;32(2):221-8. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19557750 PubMed]
<!-- Presented as oral presentations at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 29-June 2, 2009, and at the 47th Annual Meeting of ASCO, Chicago, IL, June 3-7, 2011. -->
# '''TREMPLIN:''' Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013 Mar 1;31(7):853-9. Epub 2013 Jan 22. [http://jco.ascopubs.org/content/31/7/853.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23341517 PubMed]
# '''PARADIGM:''' Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar;14(3):257-64. Epub 2013 Feb 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70011-1/fulltext link to original article] '''does not contain protocol in abstract''' [https://www.ncbi.nlm.nih.gov/pubmed/23414589 PubMed]
# Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20;31(6):744-51. Epub 2012 Nov 5. [http://ascopubs.org/doi/full/10.1200/JCO.2012.43.8820 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569675/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23129742 PubMed]
# '''TTCC XRP6976F/2503:''' Hitt R, Grau JJ, L√≥pez-Pousa A, Berrocal A, Garc√≠a-Gir√≥n C, Irigoyen A, Sastre J, Mart√≠nez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hern√°ndez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25. Epub 2013 Nov 19. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24256848 PubMed]
# '''GSTTC H&N07:''' Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codec√† C, Nol√® F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer: a phase II-III trial. Ann Oncol. 2017 Sep 1;28(9):2206-2212. [https://academic.oup.com/annonc/article/28/9/2206/3920776 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911070 PubMed]

=Locally advanced disease, definitive therapy=
==Carboplatin & RT {{#subobject:56c4ee|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:3a63ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa070956 Posner et al. 2007 (TAX 324)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|-
|}
''Reported efficacy is based on the 2011 update.'' 
====Preceding treatment====
*[[#Cisplatin_.26_Fluorouracil|CF]] versus [[#DCF|TPF]] induction

====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 1.5 IV over 60 minutes once per day on days 1, 8, 15, 22, 29, 36, 43 
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 to 37 fractions (total dose: 70 to 74 Gy), given 5 times per week over 7 to 7.5 weeks 

'''7 to 7.5-week course''' 
====Subsequent treatment====
*Patients who had an initial nodal stage of N2 and a partial response to induction chemotherapy, N3 disease, or residual disease after chemoradiotherapy: [[Surgery#Head_and_neck_cancer_surgery|Surgery]], 6 to 12 weeks after completion of chemoradiotherapy
===References===
# '''TAX 324:''' Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15. [https://www.nejm.org/doi/full/10.1056/NEJMoa070956 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17960013 PubMed]
## '''Update:''' Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR; TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb;12(2):153-9. Epub 2011 Jan 11. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356902/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21233014 PubMed]

==Carboplatin, Fluorouracil, RT {{#subobject:c1e2f9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:98c50f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article/91/24/2081/2964959 Calais et al. 1999 (GORTEC 94-01)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[https://www.redjournal.org/article/S0360-3016(01)01544-9/fulltext Staar et al. 2001]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior 1-year SLC
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70346-1/abstract Bourhis et al. 2012 (GORTEC 99-02)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. Carboplatin, Fluorouracil, accelerated concurrent RT
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Radiation_therapy|Very accelerated RT]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.76.2591 Geoffrois et al. 2018 (GORTEC 2007-02)]
|style="background-color:#1a9851"|Phase III (C)
|[[#DCF|TPF]], then [[#Cetuximab_.26_RT|Cetuximab & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] 70 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 2400 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week over 7 weeks 

'''21-day cycle for 3 cycles'''

===References===
# '''GORTEC 94-01:''' Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6. [https://academic.oup.com/jnci/article/91/24/2081/2964959 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10601378 PubMed]
## '''Update:''' Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004 Jan 1;22(1):69-76. Epub 2003 Dec 2. [http://jco.ascopubs.org/content/22/1/69.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14657228 PubMed]
# Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71. Erratum in: Int J Radiat Oncol Biol Phys 2001 Oct 1;51(2):569. [https://www.redjournal.org/article/S0360-3016(01)01544-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11483325 PubMed]
# '''GORTEC 99-02:''' Bourhis J, Sire C, Graff P, Gr√©goire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aup√©rin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012 Feb;13(2):145-53. Epub 2012 Jan 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70346-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22261362 PubMed]
# '''GORTEC 2007-02:''' Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol. 2018 Nov 1;36(31):3077-83. Epub 2018 Jul 17. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.2591 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30016178 PubMed]

==Carboplatin, Fluorouracil, Cetuximab, RT {{#subobject:db85fc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:5ae916|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.76.2518 Tao et al. 2018 (GORTEC 2007-01)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cetuximab_.26_RT|Cetuximab & RT]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] 70 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 2400 mg/m<sup>2</sup>)
*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV once on day 7, then 250 mg/m<sup>2</sup> IV once per week until end of radiation
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week over 7 weeks 

'''21-day cycle for 3 cycles'''

===References===
# '''GORTEC 2007-01:''' Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, Bardet E, Kaminsky MC, Lapeyre M, Chatellier T, Alfonsi M, Pointreau Y, Jadaud E, G√©ry B, Zawadi A, Tourani JM, Laguerre B, Coutte A, Racadot S, Hasbini A, Malaurie E, Borel C, Meert N, Cornely A, Ollivier N, Casiraghi O, Sun XS, Bourhis J. Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial. J Clin Oncol. 2018 Nov 1;36(31):3084-90. Epub 2018 Jun 7. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.2518 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29878867 PubMed]

==Carboplatin, Paclitaxel, RT {{#subobject:9cccfc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, accelerated hyperfractionated RT {{#subobject:1fecad|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs10637-008-9128-1 Carter et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] AUC 1 IV once per week
*[[Paclitaxel (Taxol)]] 40 mg/m<sup>2</sup> IV once per week
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.2 Gy twice per day fractions (total dose: 69.6 Gy)

'''6-week course of therapy'''

===Variant #2, standard RT {{#subobject:1fecad|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/9045343 Conley et al. 1997]
|style="background-color:#ffffbe"|Pilot, <20 patients
|-
|[http://www.redjournal.org/article/S0360-3016%2800%2900408-9/abstract Suntharalingam et al. 2000]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemoradiotherapy====
*[[Carboplatin (Paraplatin)]] 100 mg/m<sup>2</sup> IV once per week, '''given prior to radiation therapy'''
*[[Paclitaxel (Taxol)]] 40 mg/m<sup>2</sup> IV once per week, '''given prior to radiation therapy'''
**According to Conley et al. 1997, the initial dose was 45 mg/m<sup>2</sup>, but 40 mg/m<sup>2</sup> was subsequently used
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 39 fractions (total dose: 70.2 Gy), given 5 times per week

====Supportive medications====
*[[Dexamethasone (Decadron)]] 20 mg (route not specified) given twice, 12 and 6 hours prior to chemotherapy
*[[Diphenhydramine (Benadryl)]] 50 mg IV once prior to chemotherapy
*[[Ranitidine (Zantac)]] 50 mg IV once prior to chemotherapy
*[[Granisetron]] 1 mg IV once prior to chemotherapy

'''7.5-week course of therapy'''

===References===
# Conley B, Jacobs M, Suntharalingam M, Zacharski D, Ord RA, Gray W, Aisner J. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-78-S2-80. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9045343 PubMed]
# Suntharalingam M, Haas ML, Conley BA, Egorin MJ, Levy S, Sivasailam S, Herman JM, Jacobs MC, Gray WC, Ord RA, Aisner JA, Van Echo DA. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):49-56. [http://www.redjournal.org/article/S0360-3016%2800%2900408-9/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10758304 PubMed]
# Carter DL, Asmar L, Barrera D, Caracandas J, Dakhil JS, McCracken D, O'Rourke MA, Rosenberg RK, Boehm KA, Ilegbodu D, Reid RL. Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma. Invest New Drugs. 2008 Oct;26(5):473-81. Epub 2008 May 13. [http://link.springer.com/article/10.1007%2Fs10637-008-9128-1 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18473121 PubMed]

==Cetuximab & RT {{#subobject:5eb410|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:6e9a4f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa053422 Bonner et al. 2006 (IMCL-9815)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy_2|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/31/7/853.long Lefebvre et al. 2013 (TREMPLIN)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article/28/9/2206/3920776 Ghi et al. 2017 (GSTTC H&N07)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: all patients in TREMPLIN received conventional RT.''
====Preceding treatment====
*TREMPLIN: [[#DCF|TPF]] x 3
*GSTTC H&N07: [[#No_induction|No induction]] versus [[#DCF|TPF]] x 3
====Chemoradiotherapy====
*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV over 2 hours once 1 week before radiation therapy begins; then 250 mg/m<sup>2</sup> IV over 60 minutes once per week during course of radiation therapy
**A test dose of 20 mg IV over 10 minutes, followed by 30 minutes of observation, was given prior to the first full dose
*Concurrent [[External_beam_radiotherapy|radiation therapy]] with one of the following regimens:
**"Coventional" regimen: 2 Gy fractions x 35 fractions (total dose: 70 Gy), given once per day 5 times per week over 7 weeks 
**"Twice per day" regimen: 1.2 Gy fractions x 60 to 64 fractions (total dose: 72 to 76.8 Gy), given twice per day for a total of 10 times per week over 6 to 6.5 weeks 
**"Concomitant boost" regimen: 1.8 Gy fractions x 18 fractions (total dose: 32.4 Gy), given once per day 5 times per week for 3.6 weeks; and twice per day fractions:
***Morning dose: 1.8 Gy fractions x 12 fractions (total dose: 21.6 Gy), given 5 days per week over 2.4 weeks
***Afternoon dose: 1.5 Gy fractions x 12 fractions (total dose: 18 Gy), given 5 days per week over 2.4 weeks
***Total dose for concomitant boost regimen: 72 Gy

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 50 mg (route not specified) "or an equivalent histamine H1‚Äìreceptor antagonist" prior to [[Cetuximab (Erbitux)]]

'''One course'''
===References===
# '''IMCL-9815:''' Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78. [https://www.nejm.org/doi/full/10.1056/NEJMoa053422 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16467544 PubMed]
## '''QoL Analysis:''' Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007 Jun 1;25(16):2191-7. [http://jco.ascopubs.org/content/25/16/2191.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17538164 PubMed]
## '''Update:''' Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. Epub 2009 Nov 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70311-0/fulltext link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19897418 PubMed]
## '''Retrospective subgroup analysis:''' Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016 Apr 20;34(12):1300-8. Epub 2015 Dec 28. [http://jco.ascopubs.org/content/34/12/1300.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070577/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26712222 PubMed]
<!-- Presented as oral presentations at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 29-June 2, 2009, and at the 47th Annual Meeting of ASCO, Chicago, IL, June 3-7, 2011. -->
# '''TREMPLIN:''' Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013 Mar 1;31(7):853-9. Epub 2013 Jan 22. [http://jco.ascopubs.org/content/31/7/853.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23341517 PubMed]
# '''GSTTC H&N07:''' Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codec√† C, Nol√® F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer: a phase II-III trial. Ann Oncol. 2017 Sep 1;28(9):2206-2212. [https://academic.oup.com/annonc/article/28/9/2206/3920776 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911070 PubMed]

==Cisplatin, Fluorouracil, RT {{#subobject:4c4db1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF & RT: '''<u>C</u>'''isplatin and '''<u>F</u>'''luorouracil with concurrent '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 60/3000 x 2 {{#subobject:59e75d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199806183382503 Brizel et al. 1998]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
|style="background-color:#d9ef8b"|Might have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 12 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 3000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.2 Gy fractions given twice per day, 5 times per week (total dose: 75 Gy)

'''35-day cycle for 2 cycles'''

===Variant #2, 60/4000 x 7 {{#subobject:8b995f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/12/2/385.long Taylor et al. 1994]
|style="background-color:#1a9851"|Phase III (E)
|[[#CF|CF]], then [[#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior ORR
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 15 minutes once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week on weeks 1, 3, 5, 7, 9, 11, 13

'''14-day cycle for 7 cycles'''

===Variant #3, 75/4000 x 4 {{#subobject:b244be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/21/1/92.long Adelstein et al. 2003 (Head and Neck Intergroup)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Radiation_therapy|RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 60 to 70 Gy), given 5 times per week on weeks 1 to 3, 7 to 9

'''28-day cycle for 4 cycles'''

===Variant #4, 80/3200 x 2 {{#subobject:1ea05d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/annonc/article/28/9/2206/3920776 Ghi et al. 2017 (GSTTC H&N07)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[#No_induction|No induction]] versus [[#DCF|TPF]] x 3
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 4
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 3200 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.0 Gy fractions given once per day, 5 times per week (total dose: 70 Gy)

'''35-day cycle for 2 cycles'''

===Variant #5, 80/4000 x 2 {{#subobject:1bb0cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291097-0347%28199710%2919%3A7%3C567%3A%3AAID-HED2%3E3.0.CO%3B2-5 Adelstein et al. 1997]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#91cf60" |Seems to have superior RFS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 80 mg/m<sup>2</sup>)
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 68 to 72 Gy at 180 to 200 cGy per day

'''21-day cycle for 2 cycles'''

===Variant #6, 100/1000 x 4, alternating with RT {{#subobject:dd2f54|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199210153271602 Merlano et al. 1992]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
|style="background-color:#1a9850"|Superior OS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724854/ Lefebvre et al. 2009 (EORTC 24954)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil|Cisplatin & 5-FU]], then [[#Radiation_therapy|RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Efficacy in Merlano et al. 1992 is based on the 1995 update.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 1000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 30 fractions (total dose: 60 Gy), given 5 times per week on weeks 2, 3, 5, 6, 8, 9

'''21-day cycle for 4 cycles'''

===Variant #7, 100/3750 x 1, then 100/2150 x 2 {{#subobject:a24c53|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.redjournal.org/article/S0360-3016(05)02712-4/fulltext Bensadoun et al. 2006]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy_2|RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] as follows:
**Cycle 1: 750 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose: 3750 mg/m<sup>2</sup>)
**Cycles 2 & 3: 430 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 2150 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.2 Gy fractions given twice per day, 5 times per week (total dose: 80.4 Gy for oropharynx; 75.6 Gy for hypopharynx)

'''21-day cycle for 3 cycles'''

===Variant #8, 100/4000 x 1 {{#subobject:f7b52|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/22/14/2856.long Garden et al. 2004 (RTOG 97-03)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Cisplatin.2C_Paclitaxel.2C_RT|Cisplatin, Paclitaxel, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Fluorouracil.2C_Hydroxyurea.2C_RT|5-FU, Hydroxyurea, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this regimen is best described in the trial protocol, which is available directly from RTOG as a PDF.''
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 10 mg/m<sup>2</sup> IV over 60 minutes once per day on days 26 to 35 of radiation (10 doses total)
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on Mondays of the sixth and seventh week of radiation (total dose: 4000 mg/m<sup>2</sup>)
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week over 7 weeks 

'''7-week course of therapy'''

===References===
# Merlano M, Vitale V, Rosso R, Benasso M, Corv√≤ R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F, Margarino G, Brema F, Pastorino G, Marziano C, Grimaldi A, Scasso F, Sperati G, Pallestrini E, Garaventa G, Accomando E, Cordone G, Comella G, Daponte A, Rubagotti A, Bruzzi P, Santi L. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992 Oct 15;327(16):1115-21. [https://www.nejm.org/doi/full/10.1056/NEJM199210153271602 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1302472 PubMed]
## '''Update:''' Merlano M, Benasso M, Corv√≤ R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996 May 1;88(9):583-9. [https://www.ncbi.nlm.nih.gov/pubmed/8609658 PubMed]
# Taylor SG 4th, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, Shott S, Vokes E, Showel JL, Hutchinson JC, Witt TR, Griem KL, Hartsell WF, Kies MS, Mittal B, Rebischung JL, Coupez DJ, Desphieux JL, Bobin S, LePajolec C. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994 Feb;12(2):385-95. [http://jco.ascopubs.org/content/12/2/385.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8113846 PubMed]
# Adelstein DJ, Saxton JP, Lavertu P, Tuason L, Wood BG, Wanamaker JR, Eliachar I, Strome M, Van Kirk MA. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997 Oct;19(7):567-75. [https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291097-0347%28199710%2919%3A7%3C567%3A%3AAID-HED2%3E3.0.CO%3B2-5 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9323144 PubMed]
## '''Update:''' Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000 Feb 15;88(4):876-83. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2820000215%2988%3A4%3C876%3A%3AAID-CNCR19%3E3.0.CO%3B2-Y link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10679658 PubMed]
# Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798-804. [https://www.nejm.org/doi/full/10.1056/NEJM199806183382503 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9632446 PubMed]
# '''Head and Neck Intergroup:''' Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. [http://jco.ascopubs.org/content/21/1/92.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506176 PubMed]
# Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004 Jul 15;22(14):2856-64. [http://jco.ascopubs.org/content/22/14/2856.long link to original article] [https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7587 link to protocol]] '''contains verified protocol in supplement''' [https://www.ncbi.nlm.nih.gov/pubmed/15254053 PubMed]
# Bensadoun RJ, B√©n√©zery K, Dassonville O, Magn√© N, Poissonnet G, Rama√Øoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, G√©ry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):983-94. Epub 2006 Jan 10. [http://www.redjournal.org/article/S0360-3016(05)02712-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16376489 PubMed]
# '''EORTC 24954:''' Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. Epub 2009 Jan 27. [https://academic.oup.com/jnci/article/101/3/142/947754 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724854/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19176454 PubMed]
## '''Update:''' Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Gr√©goire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups. Long-term update of the 24954 EORTC phase III trial on larynx preservation. Eur J Cancer. 2016 Sep;65:109-12. Epub 2016 Aug 2. [https://www.ncbi.nlm.nih.gov/pubmed/27494036 PubMed]
# '''GSTTC H&N07:''' Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codec√† C, Nol√® F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer: a phase II-III trial. Ann Oncol. 2017 Sep 1;28(9):2206-2212. [https://academic.oup.com/annonc/article/28/9/2206/3920776 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911070 PubMed]

==Cisplatin & RT {{#subobject:c7061f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 6 mg/m<sup>2</sup> daily dosing {{#subobject:9a84fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1458 Jeremic et al. 2000]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 6 mg/m<sup>2</sup> IV once per day on treatment days
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.1 Gy fractions x 70 fractions, given twice per day, 5 times per week (total dose: 77 Gy)

'''7-week course'''

===Variant #2, 20 mg/m<sup>2</sup> weekly dosing {{#subobject:16f2eb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612971/ Quon et al. 2011 (ECOG E2382)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#d9ef8b" |Might have superior FFS
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, 22, 29, 36, 43
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions given 5 times per week (total dose: 70 Gy)

'''7-week course'''

===Variant #3, 30 mg/m<sup>2</sup> weekly dosing {{#subobject:71731a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/hed.23865/full Ghosh-Laskar et al. 2014]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Radiation_therapy|Accelerated RT]]<br> 2. [[#Radiation_therapy|Standard RT]]
| style="background-color:#91cf60" |Seems to have superior locoregional control
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per week
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2.0 Gy fractions given 5 times per week (total dose: 66-70 Gy)

'''7-week course'''

===Variant #4, 100 mg/m<sup>2</sup> q3wk x 2 {{#subobject:b44282|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967367/ Adelstein et al. 2010 (SWOG S0216)]
|style="background-color:#91cf61"|Phase II
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162493/ Ang et al. 2014 (RTOG 0522)]
|style="background-color:#1a9851"|Phase III (C)
|Cetuximab, Cisplatin, RT
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Preceding treatment====
*SWOG S0216: [[#DCF|TPF induction]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]] by one of the following:
**'''SWOG S0216:''' 1.8 Gy fractions x 30 fractions, given 5 times per week (total dose: 54 Gy)
***The last 12 treatments involved a boost volume, 1.5 Gy fractions x 12 fractions (dose to boost volume: 18 Gy)
**'''RTOG 0522:''' IMRT: 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 6 times per week over 6 weeks
**'''RTOG 0522:''' Accelerated radiotherapy: 42 fractions (total dose: 72 Gy), given twice per day for 12 days then once per day for 6 weeks 

'''21-day cycle for 2 cycles'''
====Subsequent treatment====
*SWOG S0216: surgical resection was considered after concomitant chemoradiotherapy for those patients with histologically confirmed residual or recurrent disease at the primary site.

===Variant #5, 100 mg/m<sup>2</sup> q3wk x 3 {{#subobject:aca3c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/21/1/92.long Adelstein et al. 2003 (Head and Neck Intergroup)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Radiation_therapy|RT]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031317 Forastiere et al. 2003 (RTOG 91-11)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#RTOG_91-11|See link]]
|[[Complex_multipart_regimens#RTOG_91-11|See link]]
|-
|[https://link.springer.com/article/10.1385%2FMO%3A21%3A2%3A095 Fountzilas et al. 2004]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://jco.ascopubs.org/content/23/34/8636.long Hitt et al. 2005]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24916 Rasch et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|IA Cisplatin & RT
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.27.4449 Rischin et al. 2010 (HeadSTART)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Tirapazamine, RT
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 Hitt et al. 2013 (TTCC XRP6976F/2503)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://jco.ascopubs.org/content/31/7/853.long Lefebvre et al. 2013 (TREMPLIN)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[#Cetuximab_.26_RT|Cetuximab & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239304/ Nguyen-Tan et al. 2014 (RTOG 0129)]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Hyperfractionated RT
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2016.4510 Siu et al. 2016 (CCTG HN.6)]
|style="background-color:#1a9851"|Phase III (C)
|Panitumumab & RT
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.2017.74.9457 Noronha et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|Weekly cisplatin & RT
|style="background-color:#91cf60"|Seems to have superior LRC
|-
|}
====Preceding treatment====
*Hitt et al. 2005: [[#Cisplatin_.26_Fluorouracil|CF]] versus [[#PCF|PCF]] induction
*TTCC XRP6976F/2503: [[#Cisplatin_.26_Fluorouracil|CF]] versus [[#DCF|TPF]] versus [[#No_induction|no induction]]
*TREMPLIN: [[#DCF|TPF induction]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]]: 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week over 7 weeks
**Hitt et al. 2005: Nodal areas not involved by tumor received 50 Gy.

====Supportive medications====
*Best described by Al-Sarraf et al. 1998
*Forced hydration: 5% dextrose in 1/2 normal saline with 40 mEq KCl, 2000 mL IV continuous infusion over 24 hours given twice, before each dose of [[Cisplatin (Platinol)]] and after the second mannitol infusion
*Mannitol 12.5 g IV bolus prior to [[Cisplatin (Platinol)]]
*5% dextrose in 1/2 normal saline with 30 mEq KCl and mannitol 25 g, 1000 mL IV over 4 hours immediately after [[Cisplatin (Platinol)]]
*[[:Category:Emesis prevention|Antiemetic]] such as:
**[[Prochlorperazine (Compazine)]] 25 mg rectal suppository given 30 minutes prior to [[Cisplatin (Platinol)]]
**[[Prochlorperazine (Compazine)]] 10 mg IM every 4 hours as needed for nausea after [[Cisplatin (Platinol)]]

'''21-day cycle for 3 cycles'''

===References===
# Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000 Apr;18(7):1458-64. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1458 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10735893 PubMed]
# '''Head and Neck Intergroup:''' Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. [http://jco.ascopubs.org/content/21/1/92.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506176 PubMed]
# '''RTOG 91-11:''' Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa031317 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14645636 PubMed]
## '''Update:''' Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/7/845.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577950/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182993 PubMed]
# Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, Athanassiou E, Tzitzikas J, Ciuleanu T, Nikolaou A, Pantelakos P, Zaraboukas T, Zamboglou N, Daniilidis J, Ghilezan N. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol. 2004;21(2):95-107. [https://link.springer.com/article/10.1385%2FMO%3A21%3A2%3A095 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15299181 PubMed]
# Hitt R, L√≥pez-Pousa A, Mart√≠nez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Mart√≠ JL, Lobo F, Pastor P, Valent√≠ V, Bel√≥n J, S√°nchez MA, Chaib C, Pallar√©s C, Ant√≥n A, Cervantes A, Paz-Ares L, Cort√©s-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. [http://jco.ascopubs.org/content/23/34/8636.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16275937 PubMed]
# '''SWOG S0216:''' Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck. 2010 Feb;32(2):221-8. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967367/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19557750 PubMed]
# Rasch CR, Hauptmann M, Schornagel J, Wijers O, Buter J, Gregor T, Wiggenraad R, de Boer JP, Ackerstaff AH, Kroger R, Hoebers FJ, Balm AJ, Hilgers FJ. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial. Cancer. 2010 May 1;116(9):2159-65. Erratum in: Cancer. 2010 Aug 1;116(15):3750. Hilgers, Frans J [added]. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.24916 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20187094 PubMed]
# '''HeadSTART:''' Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010 Jun 20;28(18):2989-95. Epub 2010 May 17. Erratum in: J Clin Oncol. 2014 May 1;32(13):1386. [http://ascopubs.org/doi/full/10.1200/JCO.2009.27.4449 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20479425 PubMed]
# '''ECOG E2382:''' Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):719-25. Epub 2010 Oct 1. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612971/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20888709 PubMed]
<!-- Presented as oral presentations at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 29-June 2, 2009, and at the 47th Annual Meeting of ASCO, Chicago, IL, June 3-7, 2011. -->
# '''TREMPLIN:''' Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, Blot E, Rives M, Reyt E, Tourani JM, Geoffrois L, Peyrade F, Guichard F, Chevalier D, Babin E, Lang P, Janot F, Calais G, Garaud P, Bardet E. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013 Mar 1;31(7):853-9. Epub 2013 Jan 22. [http://jco.ascopubs.org/content/31/7/853.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23341517 PubMed]
# '''PARADIGM:''' Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar;14(3):257-64. Epub 2013 Feb 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70011-1/fulltext link to original article] '''does not contain protocol in abstract''' [https://www.ncbi.nlm.nih.gov/pubmed/23414589 PubMed]
# '''TTCC XRP6976F/2503:''' Hitt R, Grau JJ, L√≥pez-Pousa A, Berrocal A, Garc√≠a-Gir√≥n C, Irigoyen A, Sastre J, Mart√≠nez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hern√°ndez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014 Jan;25(1):216-25. Epub 2013 Nov 19. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt461 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24256848 PubMed]
# '''RTOG 0522:''' Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20;32(27):2940-50. [http://jco.ascopubs.org/content/32/27/2940.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162493/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25154822 PubMed]
# '''RTOG 0129:''' Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014 Dec 1;32(34):3858-66. Epub 2014 Nov 3. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.3925 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239304/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25366680 PubMed]
# Ghosh-Laskar S, Kalyani N, Gupta T, Budrukkar A, Murthy V, Sengar M, Chaukar D, Pai P, Chaturvedi P, D'Cruz A, Agarwal J. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: results of a prospective randomized trial. Head Neck. 2016 Feb;38(2):202-7. Epub 2014 Sep 15. [https://onlinelibrary.wiley.com/doi/10.1002/hed.23865/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25224814 PubMed]
# '''CCTG HN.6:''' Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol. 2017 Feb;3(2):220-6. Epub 2016 Dec 8. [https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2016.4510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27930762 PubMed]
# Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018 Apr 10;36(11):1064-1072. Epub 2017 Dec 8. [http://ascopubs.org/doi/abs/10.1200/JCO.2017.74.9457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29220295 PubMed]

==Cisplatin, Paclitaxel, RT {{#subobject:d482cc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:6f799d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/22/14/2856.long Garden et al. 2004 (RTOG 97-03)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Fluorouracil.2C_Hydroxyurea.2C_RT|5-FU, Hydroxyurea, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV once each Tuesday on weeks 1 to 7, '''given prior to radiation'''
*[[Paclitaxel (Taxol)]] 30 mg/m<sup>2</sup> IV once each Monday on weeks 1 to 7, '''given prior to radiation'''
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week over 7 weeks

'''7-week course of therapy'''

===References===
# Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004 Jul 15;22(14):2856-64. [http://jco.ascopubs.org/content/22/14/2856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15254053 PubMed]

==Docetaxel, Fluorouracil, Hydroxyurea, RT {{#subobject:3a1264e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:c36cec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/11/6/721/152538 Brockstein et al. 2000]
| style="background-color:#91cf61" |Phase I/II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876357/ Cohen et al. 2014]
|style="background-color:#1a9851"|Phase III (C)
|TPF, then Docetaxel, Fluorouracil, Hydroxyurea, RT
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemoradiotherapy====
*[[Docetaxel (Taxotere)]]
*[[Fluorouracil (5-FU)]]
*[[Hydroxyurea (Hydrea)]]
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

===References===
# Brockstein B, Haraf DJ, Stenson K, Sulzen L, Witt ME, Weichselbaum RW, Vokes EE. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000 Jun;11(6):721-8. [https://academic.oup.com/annonc/article/11/6/721/152538 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10942062 PubMed]
# Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 1;32(25):2735-43. Epub 2014 Jul 21. [http://ascopubs.org/doi/full/10.1200/JCO.2013.54.6309 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876357/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25049329 PubMed]

==Fluorouracil, Hydroxyurea, RT {{#subobject:3f664e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:892cec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/22/14/2856.long Garden et al. 2004 (RTOG 97-03)]
|rowspan=2 style="background-color:#1a9851"|Randomized Phase II (E)
|1. [[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin.2C_Paclitaxel.2C_RT|Cisplatin, Paclitaxel, RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on Monday of weeks 1, 3, 5, 7, 9, 11, 13 (total dose per week: 4000 mg/m<sup>2</sup>)
**''Note: Garden et al. 2004 was not clear about the exact schedule nor duration of the continuous infusion, such as whether each continuous infusion was over 24 hours or not''
*[[Hydroxyurea (Hydrea)]] 1000 mg PO every 12 hours x 11 doses per week on weeks 1, 3, 5, 7, 9, 11, 13 (total dose per week: 11,000 mg)
**''Note: Garden et al. 2004 did not clearly specify when the doses of hydroxyurea were to be taken in relation to radiation treatments''
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 35 fractions (total dose: 70 Gy), given 5 times per week on weeks 1, 3, 5, 7, 9, 11, 13

'''13-week course of therapy'''

===References===
# Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004 Jul 15;22(14):2856-64. [http://jco.ascopubs.org/content/22/14/2856.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15254053 PubMed]

==Fluorouracil, Mitomycin, RT {{#subobject:b4274b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:16708f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.07.010 Budach et al. 2005 (ARO 95-06)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose: 3000 mg/m<sup>2</sup>)
*[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup>/day IV once per day on days 5 & 36
*Concurrent [[External_beam_radiotherapy|radiation therapy]], hyperfractionated to total dose 70.6 Gy

'''6-week course of therapy'''

===References===
# '''ARO 95-06:''' Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol. 2005 Feb 20;23(6):1125-35. [http://ascopubs.org/doi/full/10.1200/JCO.2005.07.010 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15718308 PubMed]
## '''Update:''' Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24. Epub 2015 Feb 7. [http://www.redjournal.org/article/S0360-3016(14)04534-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25670541 PubMed]

==Fluorouracil & RT {{#subobject:3a644e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
5-FU & RT: '''<u>5-F</u>'''luoro'''<u>U</u>'''racil & '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:822cab|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ajronline.org/doi/abs/10.2214/ajr.114.1.83 Gollin et al. 1972]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|rowspan=2|[http://www.redjournal.org/article/0360-3016(90)90342-H/pdf Sanch√≠z et al. 1990]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Radiation_therapy|Conventional RT]]
| style="background-color:#1a9850" |Superior OS
|-
|2. [[#Radiation_therapy|Twice-daily RT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1994.12.12.2648 Browman et al. 1994]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|RT]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
''Of historic interest. Efficacy for Gollin et al. 1972 is based on the 1976 update, for oral lesions only.''
====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]]
*Concurrent [[External_beam_radiotherapy|radiation therapy]]

===References===
# Gollin FF, Ansfield FJ, Brandenburg JH, Ramirez G, Vermund H. Combined therapy in advanced head and neck cancer: a randomized study. Am J Roentgenol Radium Ther Nucl Med. 1972 Jan;114(1):83-8. [https://www.ajronline.org/doi/abs/10.2214/ajr.114.1.83 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4550551 PubMed]
## '''Update:''' Lo TC, Wiley AL Jr, Ansfield FJ, Brandenburg JH, Davis HL Jr, Gollin FF, Johnson RO, Ramirez G, Vermund H. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol. 1976 Feb;126(2):229-35. [http://www.ajronline.org/doi/full/10.2214/ajr.126.2.229 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/175693 PubMed]
# Sanch√≠z F, Mill√° A, Torner J, Bonet F, Artola N, Carre√±o L, Moya LM, Riera D, Ripol S, Cirera L. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1347-50. [http://www.redjournal.org/article/0360-3016(90)90342-H/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2262356 PubMed]
# Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994 Dec;12(12):2648-53. [http://ascopubs.org/doi/full/10.1200/JCO.1994.12.12.2648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7989940 PubMed]

==Paclitaxel & RT {{#subobject:9c4978|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:bea7fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/13/10/1665.long Hitt et al. 2002]
|style="background-color:#91cf61"|Phase II
|-
|}
''Chemoradiotherapy starts 4 to 6 weeks after cycle 3 day 1 or as soon as patients recover from surgery (if any).''
====Preceding treatment====
*Depending on response, [[#PCF|PCF induction]] or [[Surgery#Head_and_neck_cancer_surgery|surgery]]
====Chemoradiotherapy====
*[[Paclitaxel (Taxol)]] 25 mg/m<sup>2</sup> IV over 60 minutes once per week during radiation therapy, starting on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]] to primary unresected tumors, 1.8 to 2 Gy fractions (total dose: 65 to 70 Gy). Post-operative areas received 60 Gy. Nodal areas not involved by tumor received at least 45 Gy.

====Supportive medications====
*"Usual pre-medication was given before each paclitaxel infusion" (presumably the same ones used during [[#PCF|PCF induction]]).

===References===
# Hitt R, Paz-Ares L, Brand√°riz A, Castellano D, Pe√±a C, Mill√°n JM, Calvo F, Ortiz de Urbina D, L√≥pez E, Alvarez-Vicent JJ, Cort√©s-Funes H. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol. 2002 Oct;13(10):1665-73. [http://annonc.oxfordjournals.org/content/13/10/1665.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377658 PubMed]

==Radiation therapy {{#subobject:5ac377|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ce3d2d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ajronline.org/doi/abs/10.2214/ajr.114.1.83 Gollin et al. 1972]
|style="background-color:#1a9851"|Phase III (C)
|[[#Fluorouracil_.26_RT|5-FU & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS (*)
|-
|rowspan=2|[http://www.redjournal.org/article/0360-3016(90)90342-H/pdf Sanch√≠z et al. 1990]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Fluorouracil_.26_RT|5-FU & RT]]
| style="background-color:#d73027" |Inferior OS
|-
|2. [[#Radiation_therapy|Twice-daily RT]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 Wolf et al. 1991]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199210153271602 Merlano et al. 1992]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|[http://jco.ascopubs.org/content/12/2/385.long Taylor et al. 1994]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1994.12.12.2648 Browman et al. 1994]
|style="background-color:#1a9851"|Phase III (C)
|[[#Fluorouracil_.26_RT|5-FU & RT]]
|style="background-color:#fee08b"|Might have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1998.16.4.1318 Wendt et al. 1998]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, 5-FU, LV, RT
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199806183382503 Brizel et al. 1998]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://academic.oup.com/jnci/article/91/24/2081/2964959 Calais et al. 1999 (GORTEC 94-01)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Fluorouracil.2C_RT|Carboplatin, 5-FU, RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1458 Jeremic et al. 2000]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
| style="background-color:#d73027" |Inferior OS
|-
|rowspan=2|[http://jco.ascopubs.org/content/21/1/92.long Adelstein et al. 2003 (Head and Neck Intergroup)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.thegreenjournal.com/article/S0167-8140(03)00020-3/fulltext Grau et al. 2003]
|style="background-color:#1a9851"|Phase III (C)
|Mitomycin & RT
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa031317 Forastiere et al. 2003 (RTOG 91-11)]
|style="background-color:#1a9851"|Phase III (C)
|[[Complex_multipart_regimens#RTOG_91-11|See link]]
|style="background-color:#fc8d59"|[[Complex_multipart_regimens#RTOG_91-11|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.07.010 Budach et al. 2005 (ARO 95-06)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Fluorouracil.2C_Mitomycin.2C_RT|5-FU, Mitomycin, RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://www.redjournal.org/article/S0360-3016(05)02712-4/fulltext Bensadoun et al. 2006]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa053422 Bonner et al. 2006 (IMCL-9815)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cetuximab_.26_RT|Cetuximab & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa071028 Vermorken et al. 2007 (EORTC 24971/TAX 323)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724854/ Lefebvre et al. 2009 (EORTC 24954)]
|style="background-color:#1a9851"|Phase III (E)
|[[Complex_multipart_regimens#EORTC_24954|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#EORTC_24954|See link]]
|-
|[http://jnci.oxfordjournals.org/content/101/7/498.long Pointreau et al. 2009 (GORTEC 2000-01)]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[https://journals.sagepub.com/doi/abs/10.1177/030089161009600210 Ruo Redda et al. 2010]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin_.26_RT|Carboplatin & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thegreenjournal.com/article/S0167-8140(11)00382-3/fulltext Bourhis et al. 2011]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_RT|CF & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70346-1/abstract Bourhis et al. 2012 (GORTEC 99-02)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin.2C_Fluorouracil.2C_RT|Carboplatin, 5-FU, RT]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|2. Carboplatin, 5-FU, accelerated concurrent RT
|style="background-color:#fee08b"|Might have inferior PFS
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/hed.23865/full Ghosh-Laskar et al. 2014]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
| style="background-color:#fc8d59" |Seems to have inferior locoregional control
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546524/ Yi et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT|Cisplatin & RT]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''This is included for historical context and is unlikely to be further completed. Efficacy for Gollin et al. 1972 is based on the 1976 update, for oral lesions only. Efficacy in Merlano et al. 1992 is based on the 1995 update.''
====Preceding treatment====
*RTOG 91-11: [[#Cisplatin_.26_Fluorouracil|CF]] x 3 versus [[#No_induction|no induction]]
*Taylor et al. 1994: [[#Cisplatin_.26_Fluorouracil|CF]] x 7
*GORTEC: [[#Cisplatin_.26_Fluorouracil|CF]] x 3 versus [[#DCF|TPF]] x 3
*Wolf et al. 1991: [[#Cisplatin_.26_Fluorouracil|CF]] x 3
*EORTC 24971/TAX 323: [[#Cisplatin_.26_Fluorouracil|CF]] x 4 versus [[#DCF|TPF]] x 4
*EORTC 24954: [[#Cisplatin_.26_Fluorouracil|CF]] x 4
====Radiotherapy====
*[[External beam radiotherapy]], varying regimens

===References===
# Gollin FF, Ansfield FJ, Brandenburg JH, Ramirez G, Vermund H. Combined therapy in advanced head and neck cancer: a randomized study. Am J Roentgenol Radium Ther Nucl Med. 1972 Jan;114(1):83-8. [https://www.ajronline.org/doi/abs/10.2214/ajr.114.1.83 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4550551 PubMed]
## '''Update:''' Lo TC, Wiley AL Jr, Ansfield FJ, Brandenburg JH, Davis HL Jr, Gollin FF, Johnson RO, Ramirez G, Vermund H. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol. 1976 Feb;126(2):229-35. [http://www.ajronline.org/doi/full/10.2214/ajr.126.2.229 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/175693 PubMed]
# Sanch√≠z F, Mill√° A, Torner J, Bonet F, Artola N, Carre√±o L, Moya LM, Riera D, Ripol S, Cirera L. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1347-50. [http://www.redjournal.org/article/0360-3016(90)90342-H/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2262356 PubMed]
# Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG; Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 Jun 13;324(24):1685-90. [https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2034244 PubMed]
# Merlano M, Vitale V, Rosso R, Benasso M, Corv√≤ R, Cavallari M, Sanguineti G, Bacigalupo A, Badellino F, Margarino G, Brema F, Pastorino G, Marziano C, Grimaldi A, Scasso F, Sperati G, Pallestrini E, Garaventa G, Accomando E, Cordone G, Comella G, Daponte A, Rubagotti A, Bruzzi P, Santi L. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992 Oct 15;327(16):1115-21. [https://www.nejm.org/doi/full/10.1056/NEJM199210153271602 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1302472 PubMed]
## '''Update:''' Merlano M, Benasso M, Corv√≤ R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 1996 May 1;88(9):583-9. [https://www.ncbi.nlm.nih.gov/pubmed/8609658 PubMed]
# Taylor SG 4th, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, Shott S, Vokes E, Showel JL, Hutchinson JC, Witt TR, Griem KL, Hartsell WF, Kies MS, Mittal B, Rebischung JL, Coupez DJ, Desphieux JL, Bobin S, LePajolec C. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994 Feb;12(2):385-95. [http://jco.ascopubs.org/content/12/2/385.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8113846 PubMed]
# Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol. 1994 Dec;12(12):2648-53. [http://ascopubs.org/doi/full/10.1200/JCO.1994.12.12.2648 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7989940 PubMed] 
# Wendt TG, Grabenbauer GG, R√∂del CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998 Apr;16(4):1318-24. [http://ascopubs.org/doi/full/10.1200/JCO.1998.16.4.1318 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9552032 PubMed]
# Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798-804. [https://www.nejm.org/doi/full/10.1056/NEJM199806183382503 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9632446 PubMed]
# '''GORTEC 94-01:''' Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6. [https://academic.oup.com/jnci/article/91/24/2081/2964959 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10601378 PubMed]
## '''Update:''' Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004 Jan 1;22(1):69-76. Epub 2003 Dec 2. [http://jco.ascopubs.org/content/22/1/69.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14657228 PubMed]
# Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000 Apr;18(7):1458-64. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1458 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10735893 PubMed]
# '''Head and Neck Intergroup:''' Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. [http://jco.ascopubs.org/content/21/1/92.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506176 PubMed]
# Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, Wahid I, Turkan S, Tatsuzaki H, Dinshaw KA, Overgaard J. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol. 2003 Apr;67(1):17-26. [https://www.thegreenjournal.com/article/S0167-8140(03)00020-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12758236 PubMed]
# '''RTOG 91-11:''' Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091-8. [https://www.nejm.org/doi/full/10.1056/NEJMoa031317 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14645636 PubMed]
## '''Update:''' Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52. Epub 2012 Nov 26. [http://jco.ascopubs.org/content/31/7/845.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577950/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23182993 PubMed]
# '''ARO 95-06:''' Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol. 2005 Feb 20;23(6):1125-35. [http://ascopubs.org/doi/full/10.1200/JCO.2005.07.010 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15718308 PubMed]
## '''Update:''' Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G, Marnitz S, Olze H, Wernecke KD, Ghadjar P. Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24. Epub 2015 Feb 7. [http://www.redjournal.org/article/S0360-3016(14)04534-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25670541 PubMed]
# Bensadoun RJ, B√©n√©zery K, Dassonville O, Magn√© N, Poissonnet G, Rama√Øoli A, Lemanski C, Bourdin S, Tortochaux J, Peyrade F, Marcy PY, Chamorey E, Vallicioni J, Seng H, Alzieu C, G√©ry B, Chauvel P, Schneider M, Santini J, Demard F, Calais G. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):983-94. Epub 2006 Jan 10. [http://www.redjournal.org/article/S0360-3016(05)02712-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16376489 PubMed]
# '''IMCL-9815:''' Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567-78. [https://www.nejm.org/doi/full/10.1056/NEJMoa053422 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16467544 PubMed]
## '''Update:''' Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. Epub 2009 Nov 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70311-0/fulltext link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19897418 PubMed]
## '''QoL Analysis:''' Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007 Jun 1;25(16):2191-7. [http://jco.ascopubs.org/content/25/16/2191.long link to original article] '''contains partial protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17538164 PubMed]
## '''Retrospective subgroup analysis:''' Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016 Apr 20;34(12):1300-8. Epub 2015 Dec 28. [http://jco.ascopubs.org/content/34/12/1300.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070577/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26712222 PubMed]
# '''EORTC 24971/TAX 323:''' Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704. [https://www.nejm.org/doi/full/10.1056/NEJMoa071028 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17960012 PubMed]
## '''QoL Analysis:''' van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer. 2010 Oct 12;103(8):1173-81. Epub 2010 Sep 14. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/ link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967049/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20842129 PubMed]
# '''EORTC 24954:''' Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB; EORTC Head and Neck Cancer Cooperative Group; EORTC Radiation Oncology Group. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009 Feb 4;101(3):142-52. Epub 2009 Jan 27. [https://academic.oup.com/jnci/article/101/3/142/947754 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724854/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19176454 PubMed]
## '''Update:''' Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Gr√©goire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups. Long-term update of the 24954 EORTC phase III trial on larynx preservation. Eur J Cancer. 2016 Sep;65:109-12. Epub 2016 Aug 2. [https://www.ncbi.nlm.nih.gov/pubmed/27494036 PubMed]
# '''GORTEC 2000-01:''' Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. Epub 2009 Mar 24. [http://jnci.oxfordjournals.org/content/101/7/498.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19318632 PubMed]
## '''Update:''' Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, ¬± docetaxel for larynx preservation. J Natl Cancer Inst. 2015 Dec 16;108(4). [https://academic.oup.com/jnci/article/108/4/djv368/2412557 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26681800 PubMed]
# Ruo Redda MG, Ragona R, Ricardi U, Beltramo G, Rampino M, Gabriele P, Allis S, La Porta MR, Moro G, Melano A, Gabriele AM, Tessa M, Fossati P, Orecchia R. Radiotherapy alone or with concomitant daily low-dose carboplatin in locally advanced, unresectable head and neck cancer: definitive results of a phase III study with a follow-up period of up to ten years. Tumori. 2010 Mar-Apr;96(2):246-53. [https://journals.sagepub.com/doi/abs/10.1177/030089161009600210 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20572581 PubMed]
# Bourhis J, Lapeyre M, Tortochaux J, Lusinchi A, Etessami A, Ducourtieux M, Geoffrois L, Domenge C, Verrelle P, Wibault P, Janot F, Temam S, Blanchard P, Tao YG, Auperin A; GORTEC. Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. Radiother Oncol. 2011 Jul;100(1):56-61. Epub 2011 Aug 8. [https://www.thegreenjournal.com/article/S0167-8140(11)00382-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21831465 PubMed]
# '''GORTEC 99-02:''' Bourhis J, Sire C, Graff P, Gr√©goire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aup√©rin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012 Feb;13(2):145-53. Epub 2012 Jan 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70346-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22261362 PubMed]
# Ghosh-Laskar S, Kalyani N, Gupta T, Budrukkar A, Murthy V, Sengar M, Chaukar D, Pai P, Chaturvedi P, D'Cruz A, Agarwal J. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. Head Neck. 2016 Feb;38(2):202-7. Epub 2014 Sep 15. [https://onlinelibrary.wiley.com/doi/10.1002/hed.23865/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25224814 PubMed]
# Yi J, Huang X, Xu Z, Liu S, Wang X, He X, Luo D, Luo J, Xiao J, Zhang S, Wang K, Qu Y, Tang Y, Liu W, Xu G, Gao L, Wang D. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma. Oncotarget. 2017 Jul 4;8(27):44842-44850. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546524/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28179586 PubMed]

==Surgery==
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 Wolf et al. 1991]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Fluorouracil|CF]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Of historic interest as a control comparator, only.''
====Treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Subsequent treatment====
*[[#Radiation_therapy_2|Adjuvant RT]]
===References===
# Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG; Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 Jun 13;324(24):1685-90. [https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2034244 PubMed]

=Adjuvant therapy=
==Cisplatin, Cetuximab, RT {{#subobject:6ffc67|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:3b53bc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121506/ Harari et al. 2014 (RTOG-0234)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Cisplatin_.26_RT_2|Cisplatin & RT]]
|style="background-color:#91cf60"|Seems to have superior DFS
|-
|}
''Note: the control in this trial was the historical control arm of RTOG 9501 that received chemoradiotherapy.''
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 30 mg/m<sup>2</sup> IV once per week for 6 weeks
*[[Cetuximab (Erbitux)]] as follows:
**5 to 9 days prior to RT: 400 mg/m<sup>2</sup> IV once
**During RT: 250 mg/m<sup>2</sup> IV once per week for 6 weeks
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions (total dose: 58 to 66 Gy), given 5 times per week over 5.5 to 6.5 weeks

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 to 60 minutes prior to the first dose of [[Cetuximab (Erbitux)]]
*[[Dolasetron (Anzemet)]] 100 mg IV once 30 minutes prior to [[Cisplatin (Platinol)]]

===References===
# Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014 Aug 10;32(23):2486-95. Epub 2014 Jul 7. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.9163 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121506/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25002723 PubMed] 

==Cisplatin & RT {{#subobject:90d8d0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Variant #1, 50 mg/m<sup>2</sup> weekly {{#subobject:a550e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.redjournal.org/article/0360-3016(91)90098-O/abstract Bachaud et al. 1991]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#1a9850"|Superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV bolus once per week on the first day of radiation
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.7 Gy fractions x ~32 fractions (total dose: 54 Gy), given 5 times per week, with boost to "primary site and/or cervical lymph nodes" with 1.8 to 2 Gy fractions for an additional boost dose of 11 to 16 Gy to close (<5 mm) or positive margin areas of (overall dose to these sites: 65 to 70 Gy). A boost of 11 to 20 Gy was given to metastatic nodal sites (overall dose to these sites: 65 to 74 Gy); see Bachaud et al. 1996 for details.

====Supportive medications====
*"Forced hydration" with [[Cisplatin (Platinol)]]

'''7 to 9-week course, depending on duration of radiation therapy'''

===Variant #2, 100 mg/m<sup>2</sup> x 3, 54 Gy {{#subobject:46cdc6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Bernier et al. 2004 (EORTC 22931)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 27 fractions (total dose: 54 Gy), given 5 times per week over 5.5 weeks, with boost to areas at "high risk for malignant dissemination or that had inadequate resection margins" of 2 Gy fractions x 6 fractions (boost dose: 12 Gy)

====Supportive medications====
*"Prophylactic hydration and [[:Category:Emesis prevention|antiemetic]] agents"

'''21-day cycle for 3 cycles'''

===Variant #3, 100 mg/m<sup>2</sup> x 3, 60 Gy {{#subobject:21d2ff|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032646 Cooper et al. 2004 (RTOG 9501)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Radiation_therapy|Radiation therapy]]
|style="background-color:#91cf60"|Seems to have superior DFS
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.2017.74.9457 Noronha et al. 2017]
|style="background-color:#1a9851"|Phase III (C)
|Weekly cisplatin & RT
|style="background-color:#91cf60"|Seems to have superior LRC
|-
|}
====Preceding treatment====
*RTOG 9501: Patients "had undergone macroscopically complete [[Surgery#Head_and_neck_cancer_surgery|resection]] of disease" and at least one high-risk characteristic: "histologic evidence of invasion of two or more regional lymph nodes, extracapsular extension of nodal disease, and microscopically involved mucosal margins of resection."
*Noronha et al. 2017: [[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 30 fractions (total dose: 60 Gy), given 5 times per week over 6 weeks,
**RTOG 9501: Optional boost of 2 Gy fractions x 3 fractions (boost dose: 6 Gy) to high-risk sites

====Supportive medications====
*Hydration before and after treatment
*[[:Category:Emesis prevention|Antiemetics]] per physician choice
*Optional use of feeding tubes

'''21-day cycle for 3 cycles'''

===Variant #4, 100 mg/m<sup>2</sup> x 3, 66 Gy {{#subobject:daa85b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.61.4370 Harrington et al. 2015]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin, Lapatinib, RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemoradiotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions x 33 fractions (total dose: 66 Gy), given 5 times per week

'''21-day cycle for 3 cycles'''
===References===
# Bachaud JM, David JM, Boussin G, Daly N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):243-6. [http://www.redjournal.org/article/0360-3016(91)90098-O/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1991685 PubMed] 
## '''Update:''' Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004. [http://www.redjournal.org/article/S0360-3016%2896%2900430-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8985019 PubMed]
# '''RTOG 9501:''' Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44. [https://www.nejm.org/doi/full/10.1056/NEJMoa032646 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15128893 PubMed]
## '''Posthoc analysis:''' Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lef√®bvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50. [https://onlinelibrary.wiley.com/doi/10.1002/hed.20279/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16161069 PubMed]
## '''Update:''' Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. Epub 2012 Jun 30. [http://www.redjournal.org/article/S0360-3016%2812%2900650-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465463/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22749632 PubMed]
# '''EORTC 22931:''' Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lef√®bvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa032641 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15128894 PubMed]
## '''Posthoc analysis:''' Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lef√®bvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50. [https://onlinelibrary.wiley.com/doi/10.1002/hed.20279/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16161069 PubMed]
# Harrington K, Temam S, Mehanna H, D'Cruz A, Jain M, D'Onofrio I, Manikhas G, Horvath Z, Sun Y, Dietzsch S, Dubinsky P, Holeckova P, El-Hariry I, Franklin N, Biswas-Baldwin N, Legenne P, Wissel P, Netherway T, Farrell J, Ellis C, Wang-Silvanto J, Amonkar M, Ahmed N, Santillana S, Bourhis J. Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2015 Dec 10;33(35):4202-9. Epub 2015 Nov 2. [http://ascopubs.org/doi/full/10.1200/JCO.2015.61.4370 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26527790 PubMed]
# Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018 Apr 10;36(11):1064-1072. Epub 2017 Dec 8. [http://ascopubs.org/doi/abs/10.1200/JCO.2017.74.9457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29220295 PubMed]

==Docetaxel, Cetuximab, RT {{#subobject:de2a39|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:75317a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121506/ Harari et al. 2014 (RTOG-0234)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Cisplatin_.26_RT_2|Cisplatin & RT]]
|style="background-color:#1a9850"|Superior DFS
|-
|}
''Note: the control in this trial was the historical control arm of RTOG 9501 that received chemoradiotherapy.''
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemoradiotherapy====
*[[Docetaxel (Taxotere)]] 15 mg/m<sup>2</sup> IV once per week for 6 weeks
*[[Cetuximab (Erbitux)]] as follows:
**5 to 9 days prior to RT: 400 mg/m<sup>2</sup> IV once
**During RT: 250 mg/m<sup>2</sup> IV once per week for 6 weeks
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 2 Gy fractions (total dose: 58 to 66 Gy), given 5 times per week over 5.5 to 6.5 weeks

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 50 mg IV once 30 to 60 minutes prior to the first dose of [[Cetuximab (Erbitux)]]
*[[Dexamethasone (Decadron)]] 20 mg IV once prior to [[Docetaxel (Taxotere)]]

===References===
# Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014 Aug 10;32(23):2486-95. Epub 2014 Jul 7. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.9163 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121506/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25002723 PubMed] 

==Radiation therapy {{#subobject:571927|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:9ed143|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 Wolf et al. 1991]
|style="background-color:#91cf61"|Non-randomized portion of RCT
|style="background-color:#d3d3d3"|
|style="background-color:#d3d3d3"|
|-
|[http://www.redjournal.org/article/0360-3016(91)90098-O/abstract Bachaud et al. 1991]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT_2|Cisplatin & RT]]
|style="background-color:#d73027"|Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032646 Cooper et al. 2004 (RTOG 9501, ECOG R9501, SWOG 9515)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT_2|Cisplatin & RT]]
|style="background-color:#fc8d59"|Seems to have inferior DFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032641 Bernier et al. 2004 (EORTC 22931)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_RT_2|Cisplatin & RT]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.77.0941 Porceddu et al. 2018 (TROG 05.01)]
|style="background-color:#1a9851"|Phase III (C)
|Carboplatin & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Radiotherapy====
*[[External beam radiotherapy]] of varying doses

===References===
# Bachaud JM, David JM, Boussin G, Daly N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):243-6. [http://www.redjournal.org/article/0360-3016(91)90098-O/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1991685 PubMed] 
## '''Update:''' Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004. [http://www.redjournal.org/article/S0360-3016%2896%2900430-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8985019 PubMed]
# Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG; Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 Jun 13;324(24):1685-90. [https://www.nejm.org/doi/full/10.1056/NEJM199106133242402 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2034244 PubMed]
# '''RTOG 9501:''' Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44. [https://www.nejm.org/doi/full/10.1056/NEJMoa032646 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15128893 PubMed]
## '''Posthoc analysis:''' Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lef√®bvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50. [https://onlinelibrary.wiley.com/doi/10.1002/hed.20279/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16161069 PubMed]
## '''Update:''' Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. Epub 2012 Jun 30. [http://www.redjournal.org/article/S0360-3016%2812%2900650-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465463/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22749632 PubMed]
# '''EORTC 22931:''' Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lef√®bvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52. [https://www.nejm.org/doi/full/10.1056/NEJMoa032641 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15128894 PubMed]
## '''Posthoc analysis:''' Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lef√®bvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50. [https://onlinelibrary.wiley.com/doi/10.1002/hed.20279/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16161069 PubMed]
# '''TROG 05.01:''' Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018 May 1;36(13):1275-1283. Epub 2018 Mar 14. [http://ascopubs.org/doi/full/10.1200/JCO.2017.77.0941 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29537906/ PubMed]

==Tegafur & Uracil {{#subobject:ac88ea|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b0fe3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324826/ Tsukahara et al. 2015 (ACTS-HNC)]
|style="background-color:#1a9851"|Phase III (C)
|S-1
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Head_and_neck_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Tegafur and uracil (UFT)]] 300 mg PO once per day

'''1-year course'''

===References===
# '''ACTS-HNC:''' Tsukahara K, Kubota A, Hasegawa Y, Takemura H, Terada T, Taguchi T, Nagahara K, Nakatani H, Yoshino K, Higaki Y, Iwae S, Beppu T, Hanamure Y, Tomita K, Kohno N, Kawabata K, Fukushima M, Teramukai S, Fujii M; ACTS-HNC group. Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS One. 2015 Feb 11;10(2):e0116965. eCollection 2015. [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116965 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324826/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25671770 PubMed]

=Recurrent or metastatic disease, first-line therapy=

==Carboplatin & Docetaxel {{#subobject:917402|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:86e7c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.tandfonline.com/doi/full/10.1080/07357900701209061 Samlowski et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1
*[[Docetaxel (Taxotere)]] 65 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007 Apr-May;25(3):182-8. [https://www.tandfonline.com/doi/full/10.1080/07357900701209061 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17530488 PubMed]

==Carboplatin & Fluorouracil {{#subobject:125a7d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8d4b3a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://jco.ascopubs.org/content/10/8/1245.long Forastiere et al. 1992 (SWOG-8514)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_.26_Fluorouracil_2|CF]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Methotrexate_monotherapy|MTX]]
|style="background-color:#91cf60"|Seems to have superior ORR
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 Vermorken et al. 2008 (EXTREME)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Carboplatin.2C_Fluorouracil.2C_Cetuximab|Carboplatin, Fluorouracil, Cetuximab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] 300 mg/m<sup>2</sup> IV over 5 to 10 minutes once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, start day not specified (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*"Standard antiemetic regimens"

'''28-day cycles'''

===References===
# '''SWOG-8514:''' Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, Von Hoff DD. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1245-51. [http://jco.ascopubs.org/content/10/8/1245.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1634913 PubMed]
# '''EXTREME:''' Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18784101 PubMed]

==Carboplatin, Fluorouracil, Cetuximab {{#subobject:286b8b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ed3a81|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 Vermorken et al. 2008 (EXTREME)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Carboplatin_.26_Fluorouracil|Carboplatin & Fluorouracil]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 60 minutes once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Cetuximab (Erbitux)]] '''given first before chemotherapy and ending at least 1 hour before chemotherapy starts''', as follows:
**Cycle 1: 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 8 & 15
**Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15

'''21-day cycle for up to 6 cycles'''

===References===
# '''EXTREME:''' Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18784101 PubMed]

==Cisplatin monotherapy {{#subobject:33b395|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 50 mg/m<sup>2</sup>, 2 out of 4 weeks {{#subobject:9506cd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830715)52:2%3C206::AID-CNCR2820520204%3E3.0.CO;2-J Hong et al. 1983]
|style="background-color:#1a9851"|Phase III (E)
|[[#Methotrexate_monotherapy|Methotrexate]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article-abstract/5/6/521/252049 Clavel et al. 1994]
|style="background-color:#1a9851"|Phase III (C)
|1. [[Head_and_neck_cancer_-_historical#CABO|CABO]]<br> 2. [[#Cisplatin_.26_Fluorouracil_2|CF]]
| style="background-color:#d73027" |Inferior ORR
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycles''' 

===Variant #2, 75 mg/m<sup>2</sup> q3wk {{#subobject:8e6b66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27449 Urba et al. 2012]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Pemetrexed
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #3, 80 mg/m<sup>2</sup> q3wk {{#subobject:ed1b91|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19831101)52:9%3C1563::AID-CNCR2820520904%3E3.0.CO;2-R Jacobs et al. 1983]
|style="background-color:#1a9851"|Phase III (C)
|Cisplatin & Methotrexate
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 100 mg/m<sup>2</sup> q3wk {{#subobject:ed5291|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.1992.10.2.257 Jacobs et al. 1992]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Fluorouracil_2|CF]]
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|2. [[#Fluorouracil_monotherapy|5-FU]]
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #5, 100 mg/m<sup>2</sup> q4wk {{#subobject:f5e770|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/34/8646.long Burtness et al. 2005]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Cetuximab|Cisplatin & Cetuximab]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles''' 

''Per physician discretion, patients with complete response (CR) could have treatment discontinued 2 cycles past the point at which CR was attained. Patients with partial response (PR) continued on treatment until there was evidence of CR or progression disease. Patients with stable disease (SD) could discontinue treatment after 6 cycles. Patients with progressive disease discontinued therapy.''

===References===
# Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, Fofonoff S, D'Aoust J, Shapshay S, Welch J, Levin E, Vincent M, Vaughan C, Strong S. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983 Jul 15;52(2):206-10. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830715)52:2%3C206::AID-CNCR2820520204%3E3.0.CO;2-J link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6190545 PubMed]
# Jacobs C, Meyers F, Hendrickson C, Kohler M, Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck: a Northern California Oncology Group study. Cancer. 1983 Nov 1;52(9):1563-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19831101)52:9%3C1563::AID-CNCR2820520904%3E3.0.CO;2-R link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6352004 PubMed]
# Jacobs C, Lyman G, Velez-Garc√≠a E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992 Feb;10(2):257-63. [http://ascopubs.org/doi/full/10.1200/JCO.1992.10.2.257 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1732427 PubMed]
# Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521-6. [https://academic.oup.com/annonc/article-abstract/5/6/521/252049 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7522527 PubMed]
<!-- Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, Orlando, FL, and the American Association for Cancer Research/National Cancer Institute/European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets in Cancer Therapy, November 17-21, 2003, Boston, MA. -->
# Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. [http://jco.ascopubs.org/content/23/34/8646.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16314626 PubMed]
# Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 2012 Oct 1;118(19):4694-705. Epub 2012 Mar 20. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.27449 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22434360 PubMed]

==Cisplatin & Cetuximab {{#subobject:58744c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:c40d1f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/34/8646.long Burtness et al. 2005]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_monotherapy|Cisplatin]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Cetuximab (Erbitux)]] as follows:
**Cycle 1: 200 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 125 mg/m<sup>2</sup> IV over 60 minutes once per day on days 8, 15, 22
**Subsequent cycles: 125 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15, 22

'''28-day cycles''' 

''Per physician discretion, patients with complete response (CR) could have treatment discontinued 2 cycles past the point at which CR was attained. Patients with partial response (PR) continued on treatment until there was evidence of CR or progression disease. Patients with stable disease (SD) could discontinue treatment after 6 cycles. Patients with progressive disease discontinued therapy.''

===References===
<!-- Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, Orlando, FL, and the American Association for Cancer Research/National Cancer Institute/European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets in Cancer Therapy, November 17-21, 2003, Boston, MA. -->
# Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005 Dec 1;23(34):8646-54. [http://jco.ascopubs.org/content/23/34/8646.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16314626 PubMed]

==Cisplatin & Docetaxel {{#subobject:1a9bc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a99d1f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.20.6.1593 Glisson et al. 2002]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''
===References===
# Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002 Mar 15;20(6):1593-9. [http://ascopubs.org/doi/full/10.1200/JCO.2002.20.6.1593 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11896109 PubMed]

==Cisplatin & Fluorouracil {{#subobject:b42ea5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin and '''<u>F</u>'''luorouracil
===Regimen {{#subobject:8e0178|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1992.10.2.257 Jacobs et al. 1992]
|style="background-color:#1a9851"|Phase III (E)
|1. [[#Cisplatin_monotherapy|Cisplatin]]<br> 2. [[#Fluorouracil_monotherapy|5-FU]]
| style="background-color:#91cf60" |Seems to have superior ORR
|-
|rowspan=2|[http://jco.ascopubs.org/content/10/8/1245.long Forastiere et al. 1992 (SWOG-8514)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Carboplatin_.26_Fluorouracil|Carboplatin & Fluorouracil]]
|style="background-color:#d3d3d3"|Not reported
|-
|2. [[#Methotrexate_monotherapy|MTX]]
|style="background-color:#1a9850"|Superior ORR
|-
|rowspan=2|[https://academic.oup.com/annonc/article-abstract/5/6/521/252049 Clavel et al. 1994]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[Head_and_neck_cancer_-_historical#CABO|CABO]]
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|2. [[#Cisplatin_monotherapy|Cisplatin]]
|style="background-color:#1a9850"|Superior ORR
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.3.1054 Schrijvers et al. 1998]
|style="background-color:#1a9851"|Phase III (C)
|CF & IFN alfa
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://jco.ascopubs.org/content/23/15/3562.long Gibson et al. 2005 (ECOG E1395)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_.26_Paclitaxel|CP]]
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 Vermorken et al. 2008 (EXTREME)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_Cetuximab|CF & Cetuximab]]
|style="background-color:#fc8d59"|Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70181-5/fulltext Vermorken et al. 2013 (SPECTRUM)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin.2C_Fluorouracil.2C_Panitumumab|CF & Panitumumab]]
|style="background-color:#d73027"|Inferior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
**ECOG E1395: Carboplatin AUC 6 IV once on day 1 could be substituted in patients who developed at least grade 2 neuropathy or renal impairment (CrCl less than 50 mL/min/1.73m<sup>2</sup>; note: later in Gibson et al. 2005, it says that carboplatin was used for patients who had '''CrCl less than or equal to 50 mL/min/1.73m<sup>2</sup>''')
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*Details vary per reference
*Pretreatment and posttreatment hydration and mannitol diuresis with [[Cisplatin (Platinol)]]
*"Standard antiemetic regimens"

'''21-day cycle for up to 3 cycles (Clavel et al. 1994), 6 cycles (SPECTRUM) or indefinitely, see note below''' 

''In Clavel et al. 1994, patients proceeded to cisplatin monotherapy after 3 cycles. In ECOG E1395, patients with complete response (CR) received at least 6 cycles or 2 cycles past the point at which CR was documented, whichever came later; patients with partial response (PR) continued on treatment until there was evidence of CR or progression disease; patients with stable disease (SD) could discontinue treatment after six cycles.''

===References===
# Jacobs C, Lyman G, Velez-Garc√≠a E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992 Feb;10(2):257-63. [http://ascopubs.org/doi/full/10.1200/JCO.1992.10.2.257 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1732427 PubMed]
# '''SWOG-8514:''' Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, Von Hoff DD. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1245-51. [http://jco.ascopubs.org/content/10/8/1245.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1634913 PubMed]
# Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J, Clerico M, Dalesio O, Kirkpatrick A, Snow GB. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521-6. [https://academic.oup.com/annonc/article-abstract/5/6/521/252049 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7522527 PubMed]
# Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, Robbins K, Oliveira J, Lewensohn R, Sch√ºller J, Riviere A, Arvay C, Langecker P, Jacob H, Cvitkovic E, Vokes E; Head and Neck Interferon Cooperative Study Group. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 1998 Mar;16(3):1054-9. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.3.1054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9508190 PubMed]
# '''ECOG E1395:''' Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 May 20;23(15):3562-7. [http://jco.ascopubs.org/content/23/15/3562.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15908667 PubMed]
# '''EXTREME:''' Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18784101 PubMed]
# '''SPECTRUM:''' Vermorken JB, St√∂hlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697-710. Epub 2013 Jun 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70181-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23746666 PubMed]

==Cisplatin, Fluorouracil, Cetuximab {{#subobject:efa517|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9e612b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 Vermorken et al. 2008 (EXTREME)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_2|CF]]
|style="background-color:#91cf60"|Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Cetuximab (Erbitux)]] '''given first before chemotherapy and ending at least 1 hour before chemotherapy starts''', as follows:
**Cycle 1: 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 8 & 15
**Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15

'''21-day cycle for up to 6 cycles'''

===References===
# '''EXTREME:''' Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. [https://www.nejm.org/doi/full/10.1056/NEJMoa0802656 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18784101 PubMed]

==Cisplatin, Fluorouracil, Panitumumab {{#subobject:6a95a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:959144|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70181-5/fulltext Vermorken et al. 2013 (SPECTRUM)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_2|CF]]
|style="background-color:#1a9850"|Superior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)
*[[Panitumumab (Vectibix)]] 9 mg/kg IV once on day 1

'''21-day cycle for up to 6 cycles''' 

''Patients could choose to continue panitumumab maintenance.''

===References===
# '''SPECTRUM:''' Vermorken JB, St√∂hlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697-710. Epub 2013 Jun 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70181-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23746666 PubMed]

==Cisplatin & Paclitaxel {{#subobject:976865|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CP: '''<u>C</u>'''isplatin and '''<u>P</u>'''aclitaxel
===Regimen {{#subobject:502e23|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/15/3562.long Gibson et al. 2005 (ECOG E1395)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_2|CF]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV once on day 1
**Carboplatin AUC 6 IV once on day 1 could be used in patients who developed at least grade 2 neuropathy or renal impairment (CrCl less than 50 mL/min/1.73m<sup>2</sup>; note: later in Gibson et al. 2005, it says that carboplatin was used for patients who had '''CrCl less than or equal to 50 mL/min/1.73m<sup>2</sup>''')
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*Hydration and forced diuresis (no further details given) with [[Cisplatin (Platinol)]]
*[[Dexamethasone (Decadron)]] 20 mg PO given twice, 12 and 6 hours prior to [[Paclitaxel (Taxol)]]
*[[Diphenhydramine (Benadryl)]] (no dose specified) IV within 60 minutes prior to [[Paclitaxel (Taxol)]] 
*H2 receptor antagonist (no further details given) IV within 60 minutes prior to [[Paclitaxel (Taxol)]] 

'''21-day cycles''' 

''Patients with complete response (CR) received at least 6 cycles or 2 cycles past the point at which CR was documented, whichever came later. Patients with partial response (PR) continued on treatment until there was evidence of CR or progression disease. "Patients with stable disease (SD) could discontinue treatment after six cycles."''

===References===
# '''ECOG E1395:''' Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 May 20;23(15):3562-7. [http://jco.ascopubs.org/content/23/15/3562.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15908667 PubMed]

==Fluorouracil monotherapy {{#subobject:b2c9d5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d711a3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.1992.10.2.257 Jacobs et al. 1992]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Cisplatin_.26_Fluorouracil_2|CF]]
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|2. [[#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#d3d3d3" |Not reported
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycles'''

===References===
# Jacobs C, Lyman G, Velez-Garc√≠a E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs J, Rozencweig M. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992 Feb;10(2):257-63. [http://ascopubs.org/doi/full/10.1200/JCO.1992.10.2.257 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1732427 PubMed]

==Methotrexate monotherapy {{#subobject:dc3e62|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 40 mg/m<sup>2</sup> {{#subobject:9c3a3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830715)52:2%3C206::AID-CNCR2820520204%3E3.0.CO;2-J Hong et al. 1983]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan=2|[http://jco.ascopubs.org/content/10/8/1245.long Forastiere et al. 1992 (SWOG-8514)]
|rowspan=2 style="background-color:#1a9851"|Phase III (C)
|1. [[#Carboplatin_.26_Fluorouracil|Carboplatin & Fluorouracil]]
|style="background-color:#fc8d59"|Seems to have inferior ORR
|-
|2. [[#Cisplatin_.26_Fluorouracil_2|CF]]
|style="background-color:#d73027"|Inferior ORR
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.7.1649 Schornagel et al. 1995]
|style="background-color:#1a9851"|Phase III (C)
|Edatrexate
|style="background-color:#ffffbf"|Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0530 Stewart et al. 2009]
|style="background-color:#1a9851"|Phase III (C)
|Gefitinib
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per week

====Supportive medications====
*"Standard antiemetic regimens"

'''Continued indefinitely'''

===Variant #2, 60 mg/m<sup>2</sup> {{#subobject:9c3a3f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jama/article-abstract/339124 Lane et al. 1968]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(196805)21:5%3C828::AID-CNCR2820210507%3E3.0.CO;2-Q Leone et al. 1968]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830715)52:2%3C206::AID-CNCR2820520204%3E3.0.CO;2-J Hong et al. 1983]
|style="background-color:#1a9851"|Phase III (C)
|[[#Cisplatin_monotherapy|Cisplatin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 60 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===References===
# Lane M, Moore JE 3rd, Levin H, Smith FE. Methotrexate therapy for squamous cell carcinomas of the head and neck: intermittent intravenous dose program. JAMA. 1968 May 13;204(7):561-4. [https://jamanetwork.com/journals/jama/article-abstract/339124 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/5694477 PubMed]
# Leone LA, Albala MM, Rege VB. Treatment of carcinoma of the head and neck with intravenous methotrexate. Cancer. 1968 May;21(5):828-37. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(196805)21:5%3C828::AID-CNCR2820210507%3E3.0.CO;2-Q link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/4172047 PubMed]
# Hong WK, Schaefer S, Issell B, Cummings C, Luedke D, Bromer R, Fofonoff S, D'Aoust J, Shapshay S, Welch J, Levin E, Vincent M, Vaughan C, Strong S. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983 Jul 15;52(2):206-10. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830715)52:2%3C206::AID-CNCR2820520204%3E3.0.CO;2-J link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6190545 PubMed]
# '''SWOG-8514:''' Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, Von Hoff DD. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1245-51. [http://jco.ascopubs.org/content/10/8/1245.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1634913 PubMed]
# Schornagel JH, Verweij J, de Mulder PH, Cognetti F, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, de Graeff A, Clavel M, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol. 1995 Jul;13(7):1649-55. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.7.1649 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7602354 PubMed]
# Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10;27(11):1864-71. Epub 2009 Mar 16. Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.0530 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19289630 PubMed]

=Recurrent or metastatic disease, subsequent lines of therapy=

==Afatinib monotherapy {{#subobject:b1f829|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:8c213b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70124-5/fulltext Machiels et al. 2015 (LUX-Head & Neck 1)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Methotrexate_monotherapy_2|Methotrexate]]
|style="background-color:#91cf60"|Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Afatinib (Gilotrif)]] 40 mg PO once per day

===References===
# '''LUX-Head & Neck 1:''' Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583-94. Epub 2015 Apr 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70124-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25892145 PubMed]

==Best supportive care==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70034-1/fulltext Machiels et al. 2011 (Hx-EGFr-202)]
|style="background-color:#1a9851"|Phase III (C)
|Zalutumumab
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
''No active antineoplastic treatment.''

===References===
# '''Hx-EGFr-202:''' Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, S√∏rensen P, Nielsen T, Lisby S, Clement PM. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011 Apr;12(4):333-43. Epub 2011 Mar 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70034-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21377930 PubMed]

==Cetuximab monotherapy {{#subobject:4b973b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:608595|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/16/2171.long Vermorken et al. 2007]
|style="background-color:#91cf61"|Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 Ferris et al. 2016 (CheckMate 141)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy|Nivolumab]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: Vermorken et al. 2007 gave a 20 mg test dose as part of the initial dose; this is not specified in CheckMate 141. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Chemotherapy====
*[[Cetuximab (Erbitux)]] 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once per week

===References===
# Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007 Jun 1;25(16):2171-7. [http://jco.ascopubs.org/content/25/16/2171.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17538161 PubMed]
# '''CheckMate 141:''' Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov;375(19):1856-67. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 link to original article] '''contains verified protocol'''' [https://www.ncbi.nlm.nih.gov/pubmed/27718784 PubMed]

==Docetaxel monotherapy {{#subobject:623c3f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 30 mg/m<sup>2</sup> weekly {{#subobject:65a60f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 Ferris et al. 2016 (CheckMate 141)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy|Nivolumab]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: this was the lower bound of the dose range provided in CheckMate 141.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 30 mg/m<sup>2</sup> IV once per week

'''Continued until progression'''

===Variant #2, 35 mg/m<sup>2</sup>, 3 weeks out of 4 {{#subobject:90efb2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612594/ Argiris et al. 2013 (ECOG E1302)]
| style="background-color:#1a9851" |Phase III (C)
|Docetaxel & Gefitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 40 mg/m<sup>2</sup> weekly {{#subobject:35bea2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(04)00466-6/fulltext Guardiola et al. 2004]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[#Methotrexate_monotherapy_2|Methotrexate]]
| style="background-color:#1a9850" |Superior ORR
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 Ferris et al. 2016 (CheckMate 141)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy|Nivolumab]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: this was the upper bound of the dose range provided in CheckMate 141.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===References===
# Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, Madroszyk A, Ronchin P, Schneider M, Bleuze JP, Blay JY, Pivot X. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004 Sep;40(14):2071-6. [https://www.ejcancer.com/article/S0959-8049(04)00466-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15341981 PubMed]
# '''ECOG E1302:''' Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2013 Apr 10;31(11):1405-14. Epub 2013 Mar 4. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.4272 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612594/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23460714 PubMed]
# '''CheckMate 141:''' Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov;375(19):1856-67. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718784 PubMed]

==Methotrexate monotherapy {{#subobject:0e90b2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 40 mg/m<sup>2</sup> {{#subobject:28e5b7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70124-5/fulltext Machiels et al. 2015 (LUX-Head & Neck 1)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Afatinib_monotherapy|Afatinib]]
|style="background-color:#fc8d59"|Seems to have inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 Ferris et al. 2016 (CheckMate 141)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy|Nivolumab]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: this was the lower bound of the dose range provided in CheckMate 141.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per week

====Supportive medications====
*"Standard antiemetic regimens"

'''Continued until progression'''

===Variant #2, 60 mg/m<sup>2</sup> {{#subobject:7b97c5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 Ferris et al. 2016 (CheckMate 141)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Nivolumab_monotherapy|Nivolumab]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: this was the upper bound of the dose range provided in CheckMate 141.''
====Chemotherapy====
*[[Methotrexate (MTX)]] 60 mg/m<sup>2</sup> IV once per week

'''Continued until progression'''

===References===
# '''LUX-Head & Neck 1:''' Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583-94. Epub 2015 Apr 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70124-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25892145 PubMed]
# '''CheckMate 141:''' Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov;375(19):1856-67. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718784 PubMed]

==Nivolumab monotherapy {{#subobject:6dbddc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fa63fb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
![[Levels_of_Evidence#Efficacy|Efficacy]]
![[Overall response rate|'''ORR''']]
!Comparator [[Overall response rate|'''ORR''']]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 Ferris et al. 2016 (CheckMate 141)]
|style="background-color:#1a9851"|Phase III (E)
|Investigators' choice of:<br> 1. [[#Methotrexate_monotherapy_2| Methotrexate]]<br> 2. Docetaxel<br> 3. [[#Cetuximab_monotherapy | Cetuximab]]
|style="background-color:#1a9850"|Superior OS
|13% (95% CI 9-18)
|6% (95% CI 2-12)
|-
|}
====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV over 60 minutes once on day 1

'''14-day cycles'''

===References===
# '''CheckMate 141:''' Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov;375(19):1856-67. Epub 2016 Oct 8. [https://www.nejm.org/doi/full/10.1056/NEJMoa1602252 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27718784 PubMed]

==Pembrolizumab monotherapy {{#subobject:10dd66|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 10 mg/kg {{#subobject:159704|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30066-3/fulltext Seiwert et al. 2016 (KEYNOTE-012)]
|style="background-color:#91cf61"|Phase Ib, >20 pts
|-
|}
''Note: a small number (N=7) of patients received this treatment as their first-line therapy for recurrent or metastatic disease.''
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 10 mg/kg IV once on day 1

'''14-day cycles until progression, intolerance, or maximum of 24 months'''

===Variant #2, 200 mg {{#subobject:26a704|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31999-8/fulltext Cohen et al. 2018 (KEYNOTE-040)]
| style="background-color:#1a9851" |Phase III (E)
|1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. [[#Methotrexate_monotherapy_2|MTX]]<br> 3. [[#Cetuximab_monotherapy|Cetuximab]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1

'''14-day cycles'''

===References===
# '''KEYNOTE-012:''' Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016 Jul;17(7):956-65. Epub 2016 May 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30066-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27247226 PubMed]
# '''KEYNOTE-040:''' Cohen EEW, Souli√®res D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2018 Nov 30. [Epub ahead of print] [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31999-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30509740 PubMed]

[[Category:Head and neck cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Head and neck cancers]]
